US8273354B2	NNP	O
-	:	O
Anti-RSV	JJ	O
G	NNP	O
protein	NN	O
antibodies	VBZ	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/258,260	CD	O
,	,	O
filed	VBD	O
24	CD	O
Oct.	NNP	O
2008	CD	O
,	,	O
now	RB	O
allowed	VBN	O
,	,	O
and	CC	O
claims	NNS	O
priority	NN	O
from	IN	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Applications	NNS	O
61/000,469	CD	O
filed	VBD	O
25	CD	O
Oct.	NNP	O
2007	CD	O
and	CC	O
61/089,401	CD	O
filed	VBD	O
15	CD	O
Aug.	NNP	O
2008	CD	O
.	.	O
The	DT	O
contents	NNS	O
of	IN	O
these	DT	O
documents	NNS	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
CROSS-REFERENCE	JJ	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
The	DT	O
entire	JJ	O
content	NN	O
of	IN	O
the	DT	O
following	JJ	O
electronic	JJ	O
submission	NN	O
of	IN	O
the	DT	O
sequence	NN	O
listing	NN	O
via	IN	O
the	DT	O
USPTO	NNP	O
EFS-WEB	NNP	O
server	NN	O
,	,	O
as	IN	O
authorized	JJ	O
and	CC	O
set	VBD	O
forth	NN	O
in	IN	O
MPEP	NNP	O
§1730	NNP	O
II.B.2	NNP	O
(	(	O
a	DT	O
)	)	O
(	(	O
C	NNP	O
)	)	O
,	,	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
for	IN	O
all	DT	O
purposes	NNS	O
.	.	O
The	DT	O
sequence	NN	O
listing	NN	O
is	VBZ	O
identified	VBN	O
on	IN	O
the	DT	O
electronically	RB	O
filed	VBN	O
text	NN	O
file	NN	O
as	IN	O
follows	VBZ	O
:	:	O
TECHNICAL	JJ	O
FIELD	NNP	O
The	DT	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
antibodies	NNS	O
that	WDT	O
are	VBP	O
immunoreactive	JJ	O
with	IN	O
a	DT	O
functionally	RB	O
important	JJ	O
epitope	NN	O
contained	VBN	O
on	IN	O
the	DT	O
G	NNP	O
protein	NN	O
from	IN	O
respiratory	JJ	O
syncytial	JJ	O
virus	NN	O
(	(	O
RSV	NNP	O
)	)	O
that	WDT	O
are	VBP	O
minimally	RB	O
immunogenic	JJ	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
human	JJ	O
subject	NN	O
.	.	O
These	DT	O
antibodies	NNS	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
increase	VB	O
resistance	NN	O
of	IN	O
human	JJ	O
subjects	NNS	O
against	IN	O
RSV	NNP	O
infection	NN	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
diminish	VB	O
the	DT	O
level	NN	O
of	IN	O
infection	NN	O
in	IN	O
individuals	NNS	O
already	RB	O
infected	VBD	O
or	CC	O
to	TO	O
ameliorate	VB	O
the	DT	O
symptoms	NNS	O
caused	VBN	O
by	IN	O
RSV	NNP	O
infection	NN	O
.	.	O
BACKGROUND	NNP	O
ART	NNP	O
RSV	NNP	O
infection	NN	O
has	VBZ	O
been	VBN	O
a	DT	O
longstanding	JJ	O
and	CC	O
pernicious	JJ	O
problem	NN	O
globally	RB	O
,	,	O
including	VBG	O
the	DT	O
United	NNP	O
States	NNPS	O
,	,	O
Europe	NNP	O
,	,	O
Australia	NNP	O
and	CC	O
Japan	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
particularly	RB	O
troublesome	JJ	O
in	IN	O
premature	NN	O
infants	NNS	O
,	,	O
young	JJ	O
children	NNS	O
,	,	O
and	CC	O
the	DT	O
elderly	JJ	O
,	,	O
and	CC	O
indeed	RB	O
for	IN	O
all	DT	O
individuals	NNS	O
with	IN	O
a	DT	O
weakened	VBN	O
immune	NN	O
system	NN	O
.	.	O
It	PRP	O
is	VBZ	O
estimated	VBN	O
that	IN	O
about	RB	O
two	CD	O
thirds	NNS	O
of	IN	O
children	NNS	O
below	IN	O
age	NN	O
1	CD	O
and	CC	O
almost	RB	O
all	DT	O
children	NNS	O
between	IN	O
age	NN	O
1	CD	O
and	CC	O
4	CD	O
are	VBP	O
infected	VBN	O
at	IN	O
least	JJS	O
once	RB	O
with	IN	O
RSV	NNP	O
,	,	O
with	IN	O
most	JJS	O
recovering	VBG	O
without	IN	O
any	DT	O
need	NN	O
for	IN	O
medical	JJ	O
attention	NN	O
.	.	O
However	RB	O
,	,	O
5-10	JJ	O
%	NN	O
have	VBP	O
prolonged	VBN	O
severe	JJ	O
infection	NN	O
,	,	O
a	DT	O
factor	NN	O
believed	VBN	O
to	TO	O
be	VB	O
predisposing	VBG	O
to	TO	O
wheezing	VBG	O
and	CC	O
asthma-like	JJ	O
symptoms	NNS	O
later	RB	O
in	IN	O
childhood	NN	O
.	.	O
RSV	NNP	O
has	VBZ	O
two	CD	O
major	JJ	O
surface	NN	O
glycoproteins	NNS	O
,	,	O
F	NNP	O
and	CC	O
G.	NNP	O
The	DT	O
sole	NN	O
marketed	VBD	O
monoclonal	JJ	O
antibody	NN	O
against	IN	O
RSV	NNP	O
is	VBZ	O
only	RB	O
approved	VBN	O
for	IN	O
prophylactic	JJ	O
use	NN	O
in	IN	O
premature	NN	O
infants	NNS	O
to	TO	O
prevent	VB	O
infection	NN	O
by	IN	O
RSV	NNP	O
,	,	O
and	CC	O
is	VBZ	O
directed	VBN	O
against	IN	O
the	DT	O
F	NNP	O
protein	NN	O
.	.	O
This	DT	O
antibody	NN	O
,	,	O
palivizumab	NN	O
(	(	O
Synagis®	NNP	O
,	,	O
from	IN	O
Medlmmune	NNP	O
)	)	O
is	VBZ	O
broadly	RB	O
useful	JJ	O
due	JJ	O
to	TO	O
conservation	NN	O
of	IN	O
the	DT	O
F	NNP	O
protein	NN	O
sequence	NN	O
among	IN	O
strains	NNS	O
.	.	O
By	IN	O
contrast	NN	O
,	,	O
the	DT	O
G	NNP	O
protein	NN	O
is	VBZ	O
quite	RB	O
variable	JJ	O
except	IN	O
for	IN	O
a	DT	O
central	JJ	O
“	NN	O
CX3C	NNP	O
”	NNP	O
domain	NN	O
that	WDT	O
is	VBZ	O
nearly	RB	O
invariant	JJ	O
in	IN	O
nearly	RB	O
100	CD	O
sequenced	JJ	O
strains	NNS	O
.	.	O
This	DT	O
region	NN	O
includes	VBZ	O
a	DT	O
motif	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
interact	VB	O
with	IN	O
the	DT	O
fractalkine	NN	O
receptor	NN	O
.	.	O
That	DT	O
interaction	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
the	DT	O
prolonged	JJ	O
disease	NN	O
course	NN	O
characteristic	NN	O
of	IN	O
RSV	NNP	O
by	IN	O
suppressing	VBG	O
an	DT	O
effective	JJ	O
immune	NN	O
response	NN	O
to	TO	O
the	DT	O
virus	NN	O
:	:	O
Tripp	NNP	B
,	,	I
R.	NNP	I
A	NNP	I
,	,	I
et	NN	I
al.	NN	I
,	,	I
Nature	NNP	I
Immunology	NNP	I
(	(	I
2001	CD	I
)	)	I
2:732-738	CD	I
.	.	O
This	DT	O
region	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
antagonist	NN	O
of	IN	O
the	DT	O
Toll-like	NNP	O
Receptor	NNP	O
4	CD	O
,	,	O
which	WDT	O
is	VBZ	O
again	RB	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
suppressing	VBG	O
an	DT	O
effective	JJ	O
immune	JJ	O
response	NN	O
:	:	O
Polack	NN	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
2005	CD	I
)	)	I
102:8996-9001	CD	I
;	:	O
Shingai	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Int	NNP	I
'	POS	I
l	NN	I
Immunology	NNP	I
(	(	I
2008	CD	I
)	)	I
epub	VBP	I
July	NNP	I
8	CD	I
.	.	O
Initial	JJ	O
attempts	NNS	O
at	IN	O
prophylaxis	NN	O
for	IN	O
RSV	NNP	O
by	IN	O
vaccination	NN	O
proved	VBD	O
counterproductive	JJ	O
.	.	O
Enhanced	NNP	O
disease	NN	O
and	CC	O
pulmonary	JJ	O
eosinophilia	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
vaccination	NN	O
with	IN	O
formalin	NN	O
inactivated	VBN	O
RSV	NNP	O
or	CC	O
with	IN	O
RSV	NNP	O
G	NNP	O
glycoprotein	NN	O
and	CC	O
this	DT	O
has	VBZ	O
been	VBN	O
attributed	VBN	O
to	TO	O
the	DT	O
above	NN	O
noted	VBD	O
conserved	JJ	O
sequence	NN	O
in	IN	O
the	DT	O
G	NNP	O
protein	NN	O
designated	VBD	O
CX3C	NNP	O
region	NN	O
which	WDT	O
mimics	VBZ	O
the	DT	O
chemokine	NN	O
fractalkine	NN	O
.	.	O
(	(	O
Haynes	NNPS	B
,	,	I
L.	NNP	I
M.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
2003	CD	I
)	)	I
77:9831-9844	CD	I
.	.	O
)	)	O
Passive	JJ	O
immunization	NN	O
using	VBG	O
antibodies	NNS	O
directed	VBN	O
to	TO	O
the	DT	O
G	NNP	O
protein	NN	O
has	VBZ	O
generally	RB	O
been	VBN	O
considered	VBN	O
impractical	JJ	O
due	JJ	O
to	TO	O
the	DT	O
lack	NN	O
of	IN	O
conservation	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
this	DT	O
protein	NN	O
among	IN	O
strains	NNS	O
.	.	O
It	PRP	O
has	VBZ	O
subsequently	RB	O
been	VBN	O
confirmed	VBN	O
by	IN	O
the	DT	O
same	JJ	O
group	NN	O
that	IN	O
anti-G	JJ	O
protein	NN	O
antibody	NN	O
responses	NNS	O
engendered	VBN	O
by	IN	O
RSV	NNP	O
infection	NN	O
or	CC	O
vaccination	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
inhibition	NN	O
of	IN	O
the	DT	O
binding	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
to	TO	O
the	DT	O
fractalkine	NN	O
CX3C	NNP	O
receptor	NN	O
and	CC	O
with	IN	O
modulation	NN	O
of	IN	O
RSV	NNP	O
G-protein-mediated	NNP	O
leukocyte	NN	O
chemotaxis	NN	O
(	(	O
Harcourt	NNP	B
,	,	I
J.	NNP	I
L.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
I.	NNP	I
D.	NNP	I
(	(	I
2004	CD	I
)	)	I
190:1936-1940	CD	I
)	)	O
and	CC	O
that	DT	O
inhibition	NN	O
of	IN	O
this	DT	O
binding	VBG	O
adversely	RB	O
affects	VBZ	O
T	NNP	O
cell	NN	O
responses	NNS	O
(	(	O
Harcourt	NNP	B
,	,	I
J.	NNP	I
L.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
(	(	I
2006	CD	I
)	)	I
176:1600-1608	CD	I
)	)	O
.	.	O
More	RBR	O
recent	JJ	O
vaccine	NN	O
efforts	NNS	O
have	VBP	O
avoided	VBN	O
the	DT	O
worsening	NN	O
of	IN	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
formalin	NN	O
fixed	VBN	O
vaccine	NN	O
,	,	O
but	CC	O
the	DT	O
immunity	NN	O
conferred	VBN	O
by	IN	O
the	DT	O
newer	NN	O
vaccines	NNS	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
wane	VB	O
rapidly	RB	O
(	(	O
weeks	NNS	O
to	TO	O
months	NNS	O
)	)	O
,	,	O
consistent	JJ	O
with	IN	O
the	DT	O
poor	JJ	O
immunological	JJ	O
memory	NN	O
to	TO	O
natural	JJ	O
RSV	NNP	O
:	:	O
Yu	NN	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
2008	CD	I
)	)	I
82:2350-2357	CD	I
.	.	O
Repeated	VBN	O
infection	NN	O
is	VBZ	O
common	JJ	O
for	IN	O
this	DT	O
virus	NN	O
,	,	O
unlike	IN	O
many	JJ	O
others	NNS	O
.	.	O
The	DT	O
immunosuppressive	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
may	MD	O
be	VB	O
responsible	JJ	O
for	IN	O
this	DT	O
effect	NN	O
.	.	O
Monoclonal	JJ	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
G	NNP	O
protein	NN	O
have	VBP	O
been	VBN	O
known	VBN	O
for	IN	O
over	IN	O
20	CD	O
years	NNS	O
.	.	O
Anderson	NNP	B
,	,	I
L.	NNP	I
J.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1988	CD	I
)	)	I
62:4232-4238	CD	I
describe	IN	O
the	DT	O
ability	NN	O
of	IN	O
mixtures	NNS	O
of	IN	O
F	NNP	O
and	CC	O
G	NNP	O
protein	VBP	O
monoclonal	JJ	O
antibodies	NNS	O
(	(	O
mAbs	NN	O
)	)	O
,	,	O
and	CC	O
of	IN	O
the	DT	O
individual	JJ	O
mAbs	NN	O
,	,	O
to	TO	O
neutralize	VB	O
RSV	NNP	O
.	.	O
The	DT	O
mAbs	NN	O
relevant	NN	O
to	TO	O
binding	VBG	O
G	NNP	O
protein	NN	O
,	,	O
notably	RB	O
131-2G	CD	O
,	,	O
were	VBD	O
later	RB	O
studied	VBN	O
by	IN	O
Sullender	NNP	B
,	,	I
W.	NNP	I
,	,	I
Virol	NNP	I
.	.	I
(	(	I
1995	CD	I
)	)	I
209:70-79	CD	I
in	IN	O
an	DT	O
antigenic	JJ	O
analysis	NN	O
.	.	O
This	DT	O
antibody	NN	O
was	VBD	O
found	VBN	O
to	TO	O
bind	VB	O
both	DT	O
RSV	NNP	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
representing	VBG	O
the	DT	O
major	JJ	O
strains	NNS	O
of	IN	O
RSV	NNP	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
Mekseepralard	NNP	B
,	,	I
C.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Gen.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
2006	CD	I
)	)	I
87:1267-1273	CD	I
summarize	NN	O
earlier	JJR	O
papers	NNS	O
showing	VBG	O
that	IN	O
passively	RB	O
administered	VBN	O
antibodies	NNS	O
both	DT	O
to	TO	O
F	NNP	O
and	CC	O
G	NNP	O
protein	NN	O
were	VBD	O
protective	JJ	O
against	IN	O
experimental	JJ	O
infection	NN	O
in	IN	O
rodent	NN	O
models	NNS	O
.	.	O
These	DT	O
articles	NNS	O
include	VBP	O
Routledge	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Gen.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1988	CD	I
)	)	I
69:293-303	CD	I
;	:	O
Stott	NNP	B
,	,	I
E.	NNP	I
J.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1986	CD	I
)	)	I
60:607-613	CD	I
;	:	O
Taylor	NNP	B
,	,	I
G.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Immunol	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
52:137-142	CD	I
;	:	O
and	CC	O
Walsh	NNP	B
,	,	I
E.	NNP	I
E.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Infect	NNP	I
.	.	I
Immun	NNP	I
.	.	I
(	(	I
1984	CD	I
)	)	I
43:756-758	CD	I
.	.	O
In	IN	O
the	DT	O
instant	JJ	O
article	NN	O
,	,	O
Mekseepralard	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
noted	VBD	O
that	IN	O
a	DT	O
specific	JJ	O
monoclonal	JJ	O
antibody	NN	O
raised	VBN	O
against	IN	O
the	DT	O
G	NNP	O
protein	NN	O
(	(	O
1C2	CD	O
)	)	O
required	VBN	O
glycosylation	NN	O
in	IN	O
order	NN	O
to	TO	O
neutralize	VB	O
the	DT	O
virus	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
complement	NN	O
in	IN	O
vitro	NN	O
or	CC	O
when	WRB	O
used	VBN	O
in	IN	O
vivo	NN	O
in	IN	O
mice	NN	O
.	.	O
The	DT	O
authors	NNS	O
note	VBP	O
that	IN	O
amino	JJ	O
acids	NNS	O
173-186	CD	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
are	VBP	O
conserved	VBN	O
and	CC	O
that	IN	O
1C2	CD	O
was	VBD	O
directed	VBN	O
against	IN	O
a	DT	O
conserved	JJ	O
region	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
method	NN	O
for	IN	O
preparing	VBG	O
non-immunogenic	JJ	O
antibodies	NNS	O
was	VBD	O
relatively	RB	O
crude	JJ	O
,	,	O
namely	JJ	O
chimerization	NN	O
of	IN	O
a	DT	O
murine	NN	O
Fab	NNP	O
onto	IN	O
a	DT	O
human	JJ	O
Fc	NNP	O
region	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
Corbeil	NNP	B
,	,	I
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Vaccine	NNP	I
(	(	I
1996	CD	I
)	)	I
14:521-525	CD	I
demonstrate	NN	O
that	IN	O
the	DT	O
complement	NN	O
system	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
the	DT	O
protection	NN	O
of	IN	O
mice	NN	O
from	IN	O
challenge	NN	O
with	IN	O
RSV	NNP	O
after	IN	O
passive	JJ	O
immunization	NN	O
with	IN	O
the	DT	O
murine	JJ	O
monoclonal	JJ	O
antibody	NN	O
18A2B2	CD	O
,	,	O
even	RB	O
though	IN	O
this	DT	O
antibody	NN	O
does	VBZ	O
not	RB	O
show	VB	O
neutralizing	JJ	O
capability	NN	O
in	IN	O
vitro	NN	O
.	.	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
00/43040	CD	O
describes	VBZ	O
the	DT	O
use	NN	O
of	IN	O
anti-Substance	NN	O
P	NNP	O
antibodies	NNS	O
in	IN	O
ameliorating	VBG	O
the	DT	O
airway	NN	O
inflammation	NN	O
associated	VBN	O
with	IN	O
infection	NN	O
by	IN	O
RSV	NNP	O
.	.	O
The	DT	O
production	NN	O
of	IN	O
Substance	NNP	O
P	NNP	O
,	,	O
a	DT	O
known	JJ	O
proinflammatory	NN	O
mediator	NN	O
,	,	O
is	VBZ	O
enhanced	VBN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
of	IN	O
RSV	NNP	O
and	CC	O
is	VBZ	O
absent	JJ	O
in	IN	O
mutants	NNS	O
of	IN	O
RSV	NNP	O
that	WDT	O
are	VBP	O
missing	VBG	O
the	DT	O
G	NNP	O
protein	NN	O
or	CC	O
carry	VB	O
a	DT	O
function	NN	O
defeating	VBG	O
point	NN	O
mutation	NN	O
in	IN	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
:	:	O
Haynes	NNS	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
(	(	I
2003	CD	I
)	)	I
77:9831-9844	CD	I
.	.	O
U.S.	NNP	O
patent	NN	O
publication	NN	O
2006/0018925	CD	O
describes	NNS	O
and	CC	O
claims	NNS	O
antibodies	NNS	O
and	CC	O
small	JJ	O
peptides	NNS	O
that	WDT	O
are	VBP	O
able	JJ	O
to	TO	O
block	VB	O
the	DT	O
interaction	NN	O
of	IN	O
CX3C	NNP	O
region	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
with	IN	O
its	PRP$	O
receptor	NN	O
.	.	O
These	DT	O
compositions	NNS	O
are	VBP	O
suggested	VBN	O
as	IN	O
useful	JJ	O
for	IN	O
modulating	VBG	O
RSV	NNP	O
infection	NN	O
and	CC	O
inducing	VBG	O
immunity	NN	O
.	.	O
Although	IN	O
humanization	NN	O
of	IN	O
the	DT	O
murine	NN	O
antibodies	NNS	O
employed	VBN	O
in	IN	O
the	DT	O
demonstration	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
and	CC	O
prophylactic	JJ	O
value	NN	O
of	IN	O
these	DT	O
antibodies	NNS	O
is	VBZ	O
suggested	VBN	O
,	,	O
no	DT	O
such	JJ	O
humanized	VBN	O
forms	NNS	O
were	VBD	O
actually	RB	O
produced	VBN	O
or	CC	O
described	VBN	O
.	.	O
PCT	NNP	O
publication	NN	O
WO2007/101441	NNP	O
,	,	O
assigned	VBD	O
to	TO	O
Symphogen	NNP	O
,	,	O
is	VBZ	O
directed	VBN	O
to	TO	O
recombinant	VB	O
polyclonal	JJ	O
antibodies	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
RSV	NNP	O
infections	NNS	O
.	.	O
The	DT	O
polyclonal	JJ	O
recombinant	NN	O
antibodies	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
individual	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
that	WDT	O
were	VBD	O
isolated	VBN	O
from	IN	O
human	JJ	O
serum	NN	O
.	.	O
Table	JJ	O
5	CD	O
of	IN	O
this	DT	O
publication	NN	O
describes	VBZ	O
12	CD	O
monoclonal	JJ	O
antibodies	NNS	O
that	WDT	O
are	VBP	O
said	VBD	O
to	TO	O
bind	VB	O
to	TO	O
a	DT	O
“	NN	O
conserved	VBN	O
region	NN	O
”	NN	O
at	IN	O
amino	JJ	O
acids	NNS	O
164-176	CD	O
of	IN	O
the	DT	O
RSV	NNP	O
G	NNP	O
protein	NN	O
of	IN	O
subtype	NN	O
A	NNP	O
.	.	O
Five	CD	O
of	IN	O
these	DT	O
were	VBD	O
tested	VBN	O
for	IN	O
affinity	NN	O
to	TO	O
the	DT	O
G	NNP	O
protein	NN	O
and	CC	O
affinities	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
100-500	JJ	O
μM	NNS	O
were	VBD	O
found	VBN	O
.	.	O
Two	CD	O
of	IN	O
these	DT	O
antibodies	NNS	O
were	VBD	O
tested	VBN	O
for	IN	O
neutralizing	VBG	O
ability	NN	O
using	VBG	O
the	DT	O
plaque	NN	O
reduction	NN	O
neutralization	NN	O
test	NN	O
(	(	O
PRNT	NNP	O
)	)	O
;	:	O
one	CD	O
showed	VBD	O
an	DT	O
EC50	NNP	O
value	NN	O
of	IN	O
approximately	RB	O
2.5	CD	O
μg/ml	NNS	O
and	CC	O
the	DT	O
other	JJ	O
failed	VBD	O
to	TO	O
display	VB	O
neutralization	NN	O
characteristics	NNS	O
at	IN	O
all	DT	O
.	.	O
DISCLOSURE	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Antibodies	NNP	O
that	WDT	O
are	VBP	O
specifically	RB	O
immunoreactive	JJ	O
with	IN	O
the	DT	O
RSV	NNP	O
G	NNP	O
protein	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
F	NNP	O
protein	NN	O
,	,	O
including	VBG	O
those	DT	O
that	WDT	O
are	VBP	O
immunoreactive	JJ	O
with	IN	O
strains	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
that	WDT	O
have	VBP	O
high	JJ	O
affinity	NN	O
for	IN	O
the	DT	O
G	NNP	O
protein	NN	O
and	CC	O
potent	JJ	O
neutralizing	JJ	O
ability	NN	O
,	,	O
have	VBP	O
been	VBN	O
identified	VBN	O
from	IN	O
human	JJ	O
donors	NNS	O
confirmed	VBD	O
as	IN	O
having	VBG	O
been	VBN	O
recently	RB	O
infected	VBN	O
by	IN	O
RSV	NNP	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
a	DT	O
murine	JJ	O
anti-G	JJ	O
protein	NN	O
antibody	NN	O
,	,	O
originally	RB	O
disclosed	VBN	O
by	IN	O
Anderson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1988	CD	I
)	)	I
62:4232-4238	NN	I
,	,	O
has	VBZ	O
been	VBN	O
modified	VBN	O
so	RB	O
as	IN	O
to	TO	O
minimize	VB	O
the	DT	O
chance	NN	O
of	IN	O
immunological	JJ	O
rejection	NN	O
when	WRB	O
administered	VBN	O
to	TO	O
human	JJ	O
subjects	NNS	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
and	CC	O
also	RB	O
to	TO	O
increase	VB	O
resistance	NN	O
to	TO	O
RSV	NNP	O
in	IN	O
human	JJ	O
subjects	NNS	O
.	.	O
Specifically	RB	O
,	,	O
antibodies	NNS	O
to	TO	O
the	DT	O
conserved	VBN	O
motif	NN	O
within	IN	O
positions	NNS	O
160-176	CD	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
of	IN	O
subtype	NN	O
A	DT	O
are	VBP	O
therapeutically	RB	O
effective	JJ	O
in	IN	O
clearing	VBG	O
the	DT	O
virus	NN	O
from	IN	O
subjects	NNS	O
that	WDT	O
are	VBP	O
already	RB	O
infected	VBN	O
and	CC	O
in	IN	O
reducing	VBG	O
the	DT	O
airway	NN	O
inflammation	NN	O
characteristic	NN	O
of	IN	O
RSV	NNP	O
infections	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
prophylactic	JJ	O
use	NN	O
.	.	O
Thus	RB	O
,	,	O
in	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
monoclonal	JJ	O
antibodies	NNS	O
or	CC	O
immunoreactive	JJ	O
fragments	NNS	O
thereof	VBP	O
that	IN	O
bind	VBP	O
an	DT	O
epitope	NN	O
within	IN	O
approximately	RB	O
positions	NNS	O
160-176	NNS	O
on	IN	O
the	DT	O
G	NNP	O
protein	NN	O
of	IN	O
the	DT	O
A	NNP	O
strain	NN	O
of	IN	O
RSV	NNP	O
and	CC	O
that	WDT	O
are	VBP	O
minimally	RB	O
immunogenic	JJ	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
human	JJ	O
subject	NN	O
.	.	O
These	DT	O
antibodies	NNS	O
display	VBP	O
neutralizing	VBG	O
capabilities	NNS	O
in	IN	O
standard	JJ	O
plaque	NN	O
forming	NN	O
assays	NNS	O
for	IN	O
neutralization	NN	O
of	IN	O
RSV	NNP	O
and	CC	O
demonstrate	VB	O
EC50	NNP	O
in	IN	O
such	JJ	O
assays	NNS	O
of	IN	O
<	$	O
500	CD	O
ng/ml	NN	O
,	,	O
preferably	RB	O
<	VBZ	O
200	CD	O
ng/ml	NN	O
,	,	O
more	JJR	O
preferably	RB	O
<	$	O
100	CD	O
ng/ml	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
also	RB	O
have	VBP	O
affinities	NNS	O
for	IN	O
the	DT	O
G	NNP	O
protein	NN	O
of	IN	O
RSV-A2	NNP	O
of	IN	O
<	NNP	O
1	CD	O
nM	NN	O
,	,	O
preferably	RB	O
<	VBZ	O
500	CD	O
pM	NN	O
,	,	O
more	JJR	O
preferably	RB	O
<	$	O
100	CD	O
pM	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
,	,	O
bind	NN	O
within	IN	O
30	CD	O
residues	NNS	O
of	IN	O
,	,	O
or	CC	O
directly	RB	O
to	TO	O
,	,	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
CX3C	NNP	O
chemokine	NN	O
motif	NN	O
contained	VBN	O
in	IN	O
the	DT	O
G	NNP	O
protein	NN	O
of	IN	O
RSV	NNP	O
,	,	O
in	IN	O
a	DT	O
region	NN	O
that	WDT	O
has	VBZ	O
a	DT	O
high	JJ	O
degree	NN	O
of	IN	O
amino	NN	O
acid	NN	O
identity	NN	O
across	IN	O
multiple	JJ	O
strains	NNS	O
of	IN	O
RSV	NNP	O
.	.	O
The	DT	O
CX3C	NNP	O
chemokine	NN	O
motif	NN	O
is	VBZ	O
at	IN	O
approximately	RB	O
amino	JJ	O
acid	JJ	O
positions	NNS	O
182-186	CD	O
of	IN	O
strain	NN	O
RSV-A2	NNP	O
and	CC	O
at	IN	O
the	DT	O
corresponding	JJ	O
positions	NNS	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
in	IN	O
other	JJ	O
strains	NNS	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
found	VBN	O
that	IN	O
the	DT	O
relevant	JJ	O
region	NN	O
,	,	O
within	IN	O
which	WDT	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
bind	NN	O
,	,	O
is	VBZ	O
included	VBN	O
within	IN	O
residues	NNS	O
160-176	CD	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
of	IN	O
RSV-A2	NNP	O
and	CC	O
the	DT	O
corresponding	JJ	O
positions	NNS	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
in	IN	O
other	JJ	O
strains	NNS	O
.	.	O
This	DT	O
region	NN	O
is	VBZ	O
highly	RB	O
conserved	VBN	O
within	IN	O
the	DT	O
A	NNP	O
strain	NN	O
and	CC	O
contains	VBZ	O
only	RB	O
a	DT	O
few	JJ	O
amino	NN	O
acid	NN	O
differences	NNS	O
between	IN	O
the	DT	O
A	NNP	O
and	CC	O
B	NNP	O
strains	NNS	O
.	.	O
A	DT	O
particularly	RB	O
highly	RB	O
conserved	VBN	O
region	NN	O
has	VBZ	O
the	DT	O
sequence	NN	O
HFEVFNFVPCSIC	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
at	IN	O
positions	NNS	O
164-176	CD	O
of	IN	O
RSV	NNP	O
A2	NNP	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
bind	IN	O
an	DT	O
epitope	NN	O
that	WDT	O
includes	VBZ	O
the	DT	O
sequence	NN	O
FEVFNF	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
or	CC	O
the	DT	O
sequence	NN	O
VFNFVPCSIC	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
immunoreactive	JJ	O
with	IN	O
this	DT	O
region	NN	O
of	IN	O
conserved	VBN	O
amino	NN	O
acid	NN	O
identity	NN	O
and	CC	O
,	,	O
thus	RB	O
,	,	O
with	IN	O
G	NNP	O
protein	NN	O
of	IN	O
both	DT	O
group	NN	O
A	NNP	O
and	CC	O
group	NN	O
B	NNP	O
strains	VBZ	O
of	IN	O
this	DT	O
virus	NN	O
,	,	O
and	CC	O
therefore	RB	O
with	IN	O
the	DT	O
G-protein	NNP	O
of	IN	O
most	JJS	O
strains	NNS	O
.	.	O
For	IN	O
use	NN	O
in	IN	O
the	DT	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
treat	VB	O
RSV	NNP	O
infection	NN	O
or	CC	O
to	TO	O
enhance	VB	O
resistance	NN	O
to	TO	O
RSV	NNP	O
,	,	O
the	DT	O
monoclonal	JJ	O
antibodies	NNS	O
or	CC	O
fragments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
immunoreactive	JJ	O
with	IN	O
a	DT	O
multiplicity	NN	O
of	IN	O
strains	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
and	CC	O
a	DT	O
single	JJ	O
monoclonal	JJ	O
antibody	NN	O
may	MD	O
suffice	VB	O
to	TO	O
have	VB	O
the	DT	O
desired	JJ	O
effect	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
subject	NN	O
to	TO	O
be	VB	O
treated	VBN	O
or	CC	O
to	TO	O
be	VB	O
made	VBN	O
resistant	JJ	O
may	MD	O
be	VB	O
administered	VBN	O
more	JJR	O
than	IN	O
a	DT	O
single	JJ	O
monoclonal	NN	O
antibody	NN	O
,	,	O
in	IN	O
particular	JJ	O
where	WRB	O
one	CD	O
antibody	NN	O
in	IN	O
the	DT	O
protocol	NN	O
is	VBZ	O
more	RBR	O
highly	RB	O
reactive	JJ	O
with	IN	O
the	DT	O
strains	NNS	O
of	IN	O
group	NN	O
A	NNP	O
and	CC	O
the	DT	O
other	JJ	O
more	JJR	O
highly	RB	O
reactive	JJ	O
with	IN	O
the	DT	O
strains	NNS	O
of	IN	O
group	NN	O
B	NNP	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
includes	VBZ	O
pharmaceutical	JJ	O
compositions	NNS	O
useful	JJ	O
for	IN	O
prophylaxis	NN	O
or	CC	O
treatment	NN	O
including	VBG	O
ameliorating	VBG	O
inflammation	NN	O
which	WDT	O
contain	NN	O
as	IN	O
an	DT	O
active	JJ	O
agent	NN	O
a	DT	O
single	JJ	O
antibody	NN	O
or	CC	O
immunoreactive	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
no	DT	O
more	JJR	O
than	IN	O
two	CD	O
antibodies	NNS	O
or	CC	O
fragments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Other	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
methods	NNS	O
of	IN	O
using	VBG	O
the	DT	O
antibodies	NNS	O
to	TO	O
treat	VB	O
RSV	NNP	O
in	IN	O
human	JJ	O
subjects	NNS	O
or	CC	O
to	TO	O
induce	VB	O
resistance	NN	O
in	IN	O
these	DT	O
subjects	NNS	O
.	.	O
The	DT	O
monoclonal	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
produced	VBN	O
recombinantly	RB	O
and	CC	O
therefore	RB	O
the	DT	O
invention	NN	O
also	RB	O
includes	VBZ	O
recombinant	JJ	O
materials	NNS	O
for	IN	O
such	JJ	O
production	NN	O
as	RB	O
well	RB	O
as	IN	O
cell	NN	O
lines	NNS	O
or	CC	O
immortalized	VBN	O
cells	NNS	O
and	CC	O
non-human	JJ	O
multicellular	JJ	O
organisms	NNS	O
or	CC	O
cells	NNS	O
thereof	JJ	O
,	,	O
or	CC	O
microbial	JJ	O
cells	NNS	O
,	,	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
these	DT	O
antibodies	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
cells	NNS	O
obtained	VBN	O
from	IN	O
human	JJ	O
subjects	NNS	O
are	VBP	O
produced	VBN	O
in	IN	O
“	NNP	O
immortalized	VBD	O
”	JJ	O
form	NN	O
wherein	NN	O
they	PRP	O
have	VBP	O
been	VBN	O
modified	VBN	O
to	TO	O
permit	VB	O
secretion	NN	O
of	IN	O
the	DT	O
antibodies	NNS	O
for	IN	O
a	DT	O
sufficient	JJ	O
time	NN	O
period	NN	O
that	IN	O
they	PRP	O
may	MD	O
be	VB	O
characterized	VBN	O
and	CC	O
the	DT	O
relevant	JJ	O
encoding	NN	O
sequence	NN	O
cloned	VBD	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG	NNP	O
.	.	O
1	CD	O
is	VBZ	O
a	DT	O
plot	NN	O
showing	VBG	O
the	DT	O
frequency	NN	O
in	IN	O
ppm	NN	O
of	IN	O
antibodies	NNS	O
to	TO	O
various	JJ	O
RSV	NNP	O
antigens	NNS	O
from	IN	O
human	JJ	O
subjects	NNS	O
.	.	O
The	DT	O
desired	JJ	O
strain-independent	JJ	O
anti-G	JJ	O
phenotype	NN	O
(	(	O
Gab	NNP	O
)	)	O
is	VBZ	O
quite	JJ	O
rare	JJ	O
,	,	O
around	IN	O
10	CD	O
parts	NNS	O
per	IN	O
million	CD	O
(	(	O
ppm	NN	O
)	)	O
overall	NN	O
and	CC	O
as	RB	O
low	JJ	O
as	IN	O
1	CD	O
ppm	NN	O
in	IN	O
certain	JJ	O
subjects	NNS	O
.	.	O
“	JJ	O
Mix	NNP	O
”	NN	O
refers	NNS	O
to	TO	O
antibodies	NNS	O
binding	VBG	O
both	DT	O
F	NNP	O
and	CC	O
G	NNP	O
;	:	O
as	IN	O
F	NNP	O
and	CC	O
G	NNP	O
have	VBP	O
no	DT	O
sequence	NN	O
homology	NN	O
,	,	O
the	DT	O
binding	NN	O
is	VBZ	O
likely	JJ	O
attributable	JJ	O
to	TO	O
shared	VB	O
carbohydrate	NN	O
determinants	NNS	O
.	.	O
FIG	NNP	O
.	.	O
2A	CD	O
is	VBZ	O
a	DT	O
diagram	NN	O
of	IN	O
the	DT	O
RSV	NNP	O
G	NNP	O
protein	NN	O
indicating	VBG	O
the	DT	O
CX3C	NNP	O
region	NN	O
and	CC	O
the	DT	O
location	NN	O
of	IN	O
conserved	JJ	O
disulfide	JJ	O
bonds	NNS	O
.	.	O
The	DT	O
diagrammatic	JJ	O
version	NN	O
is	VBZ	O
generic	JJ	O
to	TO	O
all	DT	O
strains	NNS	O
,	,	O
although	IN	O
the	DT	O
specific	JJ	O
numbering	NN	O
of	IN	O
positions	NNS	O
is	VBZ	O
slightly	RB	O
different	JJ	O
from	IN	O
one	CD	O
strain	NN	O
to	TO	O
the	DT	O
next	JJ	O
.	.	O
FIG	NNP	O
.	.	O
2B	CD	O
plots	NNS	O
serum	VBP	O
binding	VBG	O
from	IN	O
RSV	NNP	O
exposed	VBD	O
subjects	NNS	O
against	IN	O
a	DT	O
panel	NN	O
of	IN	O
overlapping	VBG	O
12-mer	JJ	O
peptides	NNS	O
from	IN	O
RSV	NNP	O
G	NNP	O
protein	NN	O
,	,	O
revealing	VBG	O
poor	JJ	O
immunogenicity	NN	O
of	IN	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
.	.	O
FIG	NNP	O
.	.	O
2C	CD	O
plots	NNS	O
polymorphism	NN	O
frequency	NN	O
for	IN	O
a	DT	O
collection	NN	O
of	IN	O
over	IN	O
75	CD	O
RSV	JJ	O
strains	NNS	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
position	NN	O
in	IN	O
the	DT	O
G	NNP	O
protein	NN	O
,	,	O
revealing	VBG	O
striking	JJ	O
conservation	NN	O
at	IN	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
and	CC	O
at	IN	O
the	DT	O
alternative	JJ	O
splice	NN	O
site	NN	O
that	WDT	O
creates	VBZ	O
a	DT	O
soluble	JJ	O
form	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
probing	VBG	O
an	DT	O
illustrative	JJ	O
murine	NN	O
monoclonal	JJ	O
antibody	NN	O
(	(	O
131-2G	JJ	O
)	)	O
against	IN	O
an	DT	O
array	NN	O
of	IN	O
peptides	NNS	O
with	IN	O
overlapping	VBG	O
sequences	NNS	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:8	NNP	O
,	,	O
17-23	JJ	O
)	)	O
.	.	O
This	DT	O
work	NN	O
identifies	VBZ	O
the	DT	O
epitope	NN	O
to	TO	O
which	WDT	O
the	DT	O
mAb	NN	O
binds	VBZ	O
.	.	O
In	IN	O
the	DT	O
instance	NN	O
illustrated	VBD	O
,	,	O
the	DT	O
epitope	NN	O
is	VBZ	O
within	IN	O
30	CD	O
residues	NNS	O
of	IN	O
the	DT	O
CX3C	NNP	O
motif	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:24-27	NNP	O
)	)	O
.	.	O
FIGS	NNP	O
.	.	O
4A-4D	JJ	O
:	:	O
Panels	VB	O
A	DT	O
and	CC	O
B	NNP	O
present	JJ	O
summary	JJ	O
plots	NNS	O
of	IN	O
blood	NN	O
from	IN	O
two	CD	O
donors	NNS	O
.	.	O
Panel	VB	O
A	DT	O
shows	NNS	O
a	DT	O
donor	NN	O
that	WDT	O
has	VBZ	O
a	DT	O
useful	JJ	O
frequency	NN	O
of	IN	O
Ga/Gb	NNP	O
cross-reactive	JJ	O
clones	NNS	O
.	.	O
Panel	NNP	O
B	NNP	O
shows	VBZ	O
a	DT	O
donor	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
.	.	O
Each	DT	O
point	NN	O
in	IN	O
the	DT	O
plot	NN	O
delineates	VBZ	O
the	DT	O
relative	JJ	O
binding	NN	O
to	TO	O
three	CD	O
probes	NNS	O
for	IN	O
a	DT	O
single	JJ	O
clone	NN	O
's	POS	O
secreted	VBN	O
antibody	NN	O
footprint	NN	O
.	.	O
Panel	NNP	O
C	NNP	O
is	VBZ	O
the	DT	O
quantitative	JJ	O
profile	NN	O
of	IN	O
the	DT	O
secreted	JJ	O
protein	NN	O
footprint	NN	O
of	IN	O
a	DT	O
single	JJ	O
EBV	NNP	O
transformed	VBD	O
B	NNP	O
cell	NN	O
.	.	O
Panel	NNP	O
D	NNP	O
shows	VBZ	O
the	DT	O
profiles	NNS	O
of	IN	O
4	CD	O
progeny	NNS	O
cells	NNS	O
from	IN	O
a	DT	O
HEK293	NNP	O
cell	NN	O
transformed	VBD	O
with	IN	O
antibody	NN	O
genes	NNS	O
from	IN	O
the	DT	O
cell	NN	O
in	IN	O
panel	NN	O
C.	NNP	O
This	DT	O
profile	NN	O
is	VBZ	O
identical	JJ	O
to	TO	O
that	DT	O
in	IN	O
panel	NN	O
C	NNP	O
,	,	O
within	IN	O
the	DT	O
precision	NN	O
of	IN	O
the	DT	O
assay	NN	O
as	IN	O
defined	VBN	O
by	IN	O
replicates	NNS	O
in	IN	O
panel	NN	O
D.	NNP	O
FIGS	NNP	O
.	.	O
5A-5B	JJ	O
show	NN	O
the	DT	O
sequences	NNS	O
of	IN	O
heavy	JJ	O
chains	NNS	O
(	(	O
panel	NN	O
A	DT	O
)	)	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:28-41	NNP	O
)	)	O
and	CC	O
light	JJ	O
chains	NNS	O
(	(	O
panel	NN	O
B	NNP	O
)	)	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:42-55	NNP	O
)	)	O
for	IN	O
representative	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
FIGS	NNP	O
.	.	O
6A-6F	JJ	O
show	NN	O
Biacore	NNP	O
results	NNS	O
on	IN	O
determinations	NNS	O
of	IN	O
affinity	NN	O
of	IN	O
two	CD	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
panels	NNS	O
E	NNP	O
and	CC	O
F	NNP	O
,	,	O
antibody	NN	O
3D3	CD	O
binds	VBZ	O
the	DT	O
G	NNP	O
protein	NN	O
and	CC	O
does	VBZ	O
not	RB	O
shows	VB	O
a	DT	O
barely	RB	O
detectable	JJ	O
off	RP	O
rate	NN	O
.	.	O
Panels	NNS	O
A	DT	O
and	CC	O
D	NNP	O
show	VBP	O
binding	NN	O
of	IN	O
the	DT	O
antibody	NN	O
to	TO	O
the	DT	O
sensor	NN	O
surface	NN	O
.	.	O
Panels	NNS	O
B	NNP	O
and	CC	O
E	NNP	O
show	VBP	O
the	DT	O
increase	NN	O
in	IN	O
sensor	JJ	O
signal	NN	O
as	IN	O
Ga	NNP	O
protein	NN	O
flows	VBZ	O
across	IN	O
the	DT	O
surface	NN	O
and	CC	O
is	VBZ	O
captured	VBN	O
by	IN	O
the	DT	O
bound	NN	O
antibody	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
decline	NN	O
in	IN	O
signal	NN	O
as	IN	O
the	DT	O
surface	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
buffer	NN	O
allowing	VBG	O
the	DT	O
bound	NN	O
Ga	NNP	O
protein	NN	O
to	TO	O
desorb	VB	O
from	IN	O
the	DT	O
surface	NN	O
.	.	O
Panels	NNP	O
C	NNP	O
and	CC	O
F	NNP	O
similarly	RB	O
show	VBP	O
on-rates	NNS	O
and	CC	O
off-rates	NNS	O
for	IN	O
the	DT	O
Gb	NNP	O
protein	NN	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
is	VBZ	O
a	DT	O
graph	NN	O
of	IN	O
the	DT	O
binding	NN	O
of	IN	O
various	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
Synagis®	NNP	O
F	NNP	O
protein-binding	JJ	O
antibody	NN	O
as	IN	O
determined	VBN	O
in	IN	O
an	DT	O
ELISA	NNP	O
assay	VBP	O
using	VBG	O
live	JJ	O
virus	NN	O
to	TO	O
coat	VB	O
the	DT	O
microplate	NN	O
.	.	O
FIG	NNP	O
.	.	O
8	CD	O
is	VBZ	O
a	DT	O
graph	NN	O
plotting	VBG	O
affinity	NN	O
to	TO	O
G	NNP	O
protein	NN	O
on	IN	O
the	DT	O
X-axis	NNP	O
against	IN	O
binding	VBG	O
to	TO	O
virus	VB	O
on	IN	O
the	DT	O
Y-axis	NNP	O
.	.	O
The	DT	O
two	CD	O
abilities	NNS	O
are	VBP	O
correlated	VBN	O
,	,	O
although	IN	O
3D3	CD	O
shows	NNS	O
slightly	RB	O
less	JJR	O
affinity	NN	O
to	TO	O
live	VB	O
virus	NN	O
than	IN	O
would	MD	O
be	VB	O
predicted	VBN	O
from	IN	O
its	PRP$	O
affinity	NN	O
to	TO	O
G	NNP	O
protein	NN	O
.	.	O
FIGS	NNP	O
.	.	O
9A	CD	O
and	CC	O
9B	CD	O
show	VBP	O
a	DT	O
comparison	NN	O
of	IN	O
binding	NN	O
of	IN	O
several	JJ	O
antibodies	NNS	O
to	TO	O
strains	NNS	O
A2	NNP	O
and	CC	O
A5	NNP	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
neutralization	NN	O
assays	NNS	O
.	.	O
The	DT	O
results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
number	NN	O
of	IN	O
plaques	NNS	O
plotted	VBN	O
against	IN	O
μg	NN	O
of	IN	O
antibody	NN	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
shows	VBZ	O
a	DT	O
comparison	NN	O
of	IN	O
antibody	NN	O
3G12	CD	O
of	IN	O
the	DT	O
invention	NN	O
with	IN	O
Synagis®	NNP	O
in	IN	O
neutralizing	VBG	O
RSV	NNP	O
strain	NN	O
B	NNP	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
shows	VBZ	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
prophylactic	JJ	O
activity	NN	O
of	IN	O
two	CD	O
invention	NN	O
antibodies	NNS	O
with	IN	O
Synagis®	NNP	O
commercial	JJ	O
antibody	NN	O
.	.	O
FIGS	NNP	O
.	.	O
13A-13C	JJ	O
show	NN	O
therapeutic	JJ	O
efficacy	NN	O
of	IN	O
mAb	JJ	O
131-2G	JJ	O
in	IN	O
a	DT	O
post-infection	JJ	O
murine	NN	O
model	NN	O
of	IN	O
RSV	NNP	O
(	(	O
treatment	NN	O
at	IN	O
day	NN	O
+3	NNP	O
post-infection	NN	O
)	)	O
,	,	O
including	VBG	O
dose	JJ	O
dependent	JJ	O
reduction	NN	O
in	IN	O
viral	JJ	O
load	NN	O
(	(	O
panel	NN	O
A	DT	O
)	)	O
along	IN	O
with	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
reduced	JJ	O
lung	NN	O
inflammation	NN	O
:	:	O
NK	NNP	O
cells	NNS	O
and	CC	O
PMN	NNP	O
cells	NNS	O
(	(	O
panel	NN	O
B	NNP	O
)	)	O
and	CC	O
interferon-gamma	JJ	O
(	(	O
IFNγ	NNP	O
)	)	O
(	(	O
panel	NN	O
C	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
14	CD	O
shows	VBZ	O
the	DT	O
time	NN	O
course	NN	O
of	IN	O
viral	JJ	O
titer	NN	O
in	IN	O
a	DT	O
mouse	NN	O
model	NN	O
treated	VBD	O
with	IN	O
3G12	CD	O
,	,	O
3D3	CD	O
or	CC	O
Synagis®	NNP	O
antibodies	NNS	O
at	IN	O
a	DT	O
low	JJ	O
dose	NN	O
that	WDT	O
highlights	VBZ	O
the	DT	O
potency	NN	O
advantage	NN	O
of	IN	O
the	DT	O
high	JJ	O
affinity	NN	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
FIG	NNP	O
.	.	O
15	CD	O
is	VBZ	O
a	DT	O
dose/response	JJ	O
curve	NN	O
measuring	VBG	O
the	DT	O
effect	NN	O
of	IN	O
antibodies	NNS	O
on	IN	O
RSV	NNP	O
copy	NN	O
number	NN	O
in	IN	O
the	DT	O
lungs	NNS	O
of	IN	O
RSV-infected	NNP	O
mice	NN	O
when	WRB	O
treated	VBN	O
at	IN	O
day	NN	O
+3	NNP	O
after	IN	O
infection	NN	O
.	.	O
FIG	NNP	O
.	.	O
16	CD	O
shows	NNS	O
comparative	JJ	O
ability	NN	O
of	IN	O
Synagis®	NNP	O
,	,	O
3D3	CD	O
and	CC	O
3G12	CD	O
to	TO	O
reduce	VB	O
viral	JJ	O
load	NN	O
at	IN	O
the	DT	O
end	NN	O
stages	NNS	O
of	IN	O
infection	NN	O
,	,	O
after	IN	O
treatment	NN	O
at	IN	O
day	NN	O
+3	NNP	O
after	IN	O
infection	NN	O
.	.	O
FIG	NNP	O
.	.	O
17	CD	O
shows	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
control	NN	O
antibody	NN	O
,	,	O
anti-F	JJ	O
antibody	NN	O
and	CC	O
anti-G	JJ	O
antibody	NN	O
on	IN	O
BAL	NNP	O
cells	NNS	O
in	IN	O
the	DT	O
lungs	NNS	O
of	IN	O
RSV-infected	JJ	O
mice	NN	O
.	.	O
Treatment	NN	O
was	VBD	O
at	IN	O
day	NN	O
+3	CD	O
post-infection	NN	O
.	.	O
FIGS	NNP	O
.	.	O
18A	CD	O
and	CC	O
18B	CD	O
show	NN	O
that	WDT	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
immunospecific	JJ	O
fragments	NNS	O
of	IN	O
anti-G	JJ	O
mAb	NNS	O
are	VBP	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
intact	JJ	O
mAbs	NN	O
in	IN	O
reducing	VBG	O
inflammation	NN	O
in	IN	O
RSV-infected	NNP	O
mice	NN	O
when	WRB	O
given	VBN	O
at	IN	O
day	NN	O
+3	NNP	O
post-infection	NN	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
viral	JJ	O
load	NN	O
.	.	O
FIGS	NNP	O
.	.	O
19A-19C	JJ	O
show	NN	O
the	DT	O
effect	NN	O
of	IN	O
anti-G	JJ	O
mAbs	NN	O
on	IN	O
the	DT	O
production	NN	O
of	IN	O
IFNγ	NNP	O
in	IN	O
BAL	NNP	O
at	IN	O
various	JJ	O
times	NNS	O
of	IN	O
administration	NN	O
of	IN	O
the	DT	O
antibody	NN	O
,	,	O
ranging	VBG	O
from	IN	O
prophylactic	JJ	O
(	(	O
day	NN	O
−1	NNP	O
)	)	O
to	TO	O
day	NN	O
+3	NNP	O
and	CC	O
day	NN	O
+5	NNP	O
post-infection	NN	O
.	.	O
FIG	NNP	O
.	.	O
20	CD	O
shows	NNS	O
antibody	VBP	O
titer	NN	O
to	TO	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
of	IN	O
RSV	NNP	O
G	NNP	O
protein	NN	O
from	IN	O
elderly	JJ	O
patients	NNS	O
infected	VBN	O
with	IN	O
RSV	NNP	O
.	.	O
The	DT	O
patients	NNS	O
were	VBD	O
selected	VBN	O
according	VBG	O
to	TO	O
severity	NN	O
of	IN	O
clinical	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
,	,	O
severe	EX	O
or	CC	O
mild	NN	O
.	.	O
The	DT	O
absence	NN	O
of	IN	O
appreciable	JJ	O
titer	NN	O
to	TO	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
is	VBZ	O
correlated	VBN	O
with	IN	O
severe	JJ	O
disease	NN	O
.	.	O
MODES	NNP	O
OF	NNP	O
CARRYING	NNP	O
OUT	NNP	O
THE	NNP	O
INVENTION	NNP	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
treat	NN	O
”	NN	O
refers	NNS	O
to	TO	O
reducing	VBG	O
the	DT	O
viral	JJ	O
burden	NN	O
in	IN	O
a	DT	O
subject	NN	O
that	WDT	O
is	VBZ	O
already	RB	O
infected	VBN	O
with	IN	O
RSV	NNP	O
or	CC	O
to	TO	O
ameliorating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
the	DT	O
disease	NN	O
in	IN	O
such	JJ	O
a	DT	O
subject	NN	O
.	.	O
Such	JJ	O
symptoms	NNS	O
include	VBP	O
bronchiolitis	NN	O
,	,	O
airway	JJ	O
inflammation	NN	O
,	,	O
congestion	NN	O
in	IN	O
the	DT	O
lungs	NNS	O
,	,	O
and	CC	O
difficulty	NN	O
breathing	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
confers	NNS	O
resistance	NN	O
to	TO	O
”	VB	O
refers	NNS	O
to	TO	O
a	DT	O
prophylactic	JJ	O
effect	NN	O
wherein	VBZ	O
viral	JJ	O
infection	NN	O
by	IN	O
RSV	NNP	O
upon	IN	O
challenge	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
reduced	VBN	O
in	IN	O
severity	NN	O
.	.	O
“	NNS	O
Immortalized	NNP	O
cells	NNS	O
”	VBZ	O
refers	NNS	O
to	TO	O
cells	NNS	O
that	WDT	O
can	MD	O
survive	VB	O
significantly	RB	O
more	RBR	O
passages	NNS	O
than	IN	O
unmodified	JJ	O
primary	JJ	O
isolated	JJ	O
cells	NNS	O
.	.	O
As	IN	O
used	VBN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
“	NNP	O
immortalized	VBD	O
”	NN	O
does	VBZ	O
not	RB	O
necessarily	RB	O
mean	VB	O
that	IN	O
the	DT	O
cells	NNS	O
continue	VBP	O
to	TO	O
secrete	VB	O
antibodies	NNS	O
over	IN	O
very	RB	O
long	JJ	O
periods	NNS	O
of	IN	O
time	NN	O
,	,	O
only	RB	O
that	IN	O
they	PRP	O
can	MD	O
survive	VB	O
longer	JJR	O
than	IN	O
primary	JJ	O
cell	NN	O
cultures	NNS	O
.	.	O
The	DT	O
time	NN	O
over	IN	O
which	WDT	O
secretion	NN	O
of	IN	O
antibody	NN	O
occurs	NNS	O
need	VBP	O
only	RB	O
be	VB	O
sufficient	JJ	O
for	IN	O
its	PRP$	O
identification	NN	O
and	CC	O
recovery	NN	O
of	IN	O
the	DT	O
encoding	VBG	O
nucleotide	JJ	O
sequence	NN	O
.	.	O
The	DT	O
phrase	NN	O
“	NNP	O
minimally	RB	O
immunogenic	JJ	O
when	WRB	O
administered	VBN	O
to	TO	O
human	JJ	O
subjects	NNS	O
”	VBP	O
means	VBZ	O
that	IN	O
the	DT	O
response	NN	O
to	TO	O
administration	NN	O
in	IN	O
humans	NNS	O
is	VBZ	O
similar	JJ	O
to	TO	O
that	DT	O
obtained	VBD	O
when	WRB	O
human	JJ	O
or	CC	O
humanized	VBN	O
antibodies	NNS	O
are	VBP	O
administered	VBN	O
to	TO	O
such	JJ	O
humans	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
human	NN	O
or	CC	O
humanized	VBN	O
antibodies	NNS	O
do	VBP	O
elicit	VB	O
a	DT	O
response	NN	O
in	IN	O
5-10	JJ	O
%	NN	O
of	IN	O
humans	NNS	O
treated	VBN	O
.	.	O
This	DT	O
is	VBZ	O
true	JJ	O
even	RB	O
of	IN	O
antibodies	NNS	O
that	WDT	O
are	VBP	O
isolated	VBN	O
from	IN	O
humans	NNS	O
since	IN	O
there	EX	O
is	VBZ	O
a	DT	O
certain	JJ	O
level	NN	O
of	IN	O
background	NN	O
“	NNP	O
noise	NN	O
”	NN	O
in	IN	O
an	DT	O
immune	JJ	O
response	NN	O
elicited	VBD	O
.	.	O
The	DT	O
immune	JJ	O
response	NN	O
may	MD	O
be	VB	O
humoral	JJ	O
or	CC	O
cellular	JJ	O
or	CC	O
both	DT	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
elevated	JJ	O
levels	NNS	O
of	IN	O
cytokines	NNS	O
may	MD	O
be	VB	O
found	VBN	O
in	IN	O
this	DT	O
percentage	NN	O
of	IN	O
individuals	NNS	O
.	.	O
The	DT	O
phrase	NN	O
“	NNP	O
conserved	VBD	O
region	NN	O
of	IN	O
the	DT	O
RSV	NNP	O
G	NNP	O
protein	NN	O
”	VBZ	O
refers	NNS	O
to	TO	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
contained	VBD	O
within	IN	O
50	CD	O
amino	JJ	O
acids	NNS	O
,	,	O
preferably	RB	O
30	CD	O
amino	JJ	O
acids	NNS	O
,	,	O
more	JJR	O
preferably	RB	O
20	CD	O
amino	JJ	O
acids	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
the	DT	O
CX3C	NNP	O
region	NN	O
,	,	O
which	WDT	O
is	VBZ	O
illustrated	VBN	O
for	IN	O
a	DT	O
particular	JJ	O
strain	NN	O
in	IN	O
FIG	NNP	O
.	.	O
2A	CD	O
.	.	O
The	DT	O
conserved	JJ	O
region	NN	O
extends	VBZ	O
mostly	RB	O
at	IN	O
the	DT	O
upstream	JJ	O
portion	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
from	IN	O
the	DT	O
CX3C-specific	JJ	O
region	NN	O
.	.	O
Thus	RB	O
,	,	O
using	VBG	O
RSV	NNP	O
G	NNP	O
protein	NN	O
of	IN	O
strain	NN	O
A2	NNP	O
as	IN	O
a	DT	O
model	NN	O
,	,	O
the	DT	O
conserved	JJ	O
region	NN	O
applicable	JJ	O
to	TO	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
extends	VBZ	O
from	IN	O
approximately	RB	O
residue	JJ	O
160	CD	O
through	IN	O
188	CD	O
,	,	O
preferably	RB	O
160-176	CD	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
a	DT	O
number	NN	O
of	IN	O
desirable	JJ	O
properties	NNS	O
.	.	O
First	RB	O
,	,	O
they	PRP	O
are	VBP	O
immunoreactive	JJ	O
with	IN	O
G	NNP	O
protein	NN	O
from	IN	O
a	DT	O
multiplicity	NN	O
of	IN	O
RSV	NNP	O
strains	NNS	O
,	,	O
and	CC	O
are	VBP	O
typically	RB	O
immunoreactive	JJ	O
with	IN	O
G	NNP	O
proteins	NNS	O
both	DT	O
from	IN	O
A	NNP	O
type	NN	O
strains	NNS	O
and	CC	O
B	NNP	O
type	NN	O
strains	NNS	O
.	.	O
Second	LS	O
,	,	O
they	PRP	O
have	VBP	O
quite	RB	O
high	JJ	O
affinities	NNS	O
for	IN	O
the	DT	O
G	NNP	O
protein	NN	O
,	,	O
some	DT	O
of	IN	O
them	PRP	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
<	$	O
2	CD	O
pM	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
affinities	NNS	O
of	IN	O
at	IN	O
least	JJS	O
10	CD	O
nM	NN	O
,	,	O
preferably	RB	O
1	CD	O
nM	NNS	O
,	,	O
more	JJR	O
preferably	RB	O
500	CD	O
pM	NN	O
,	,	O
more	JJR	O
preferably	RB	O
100	CD	O
pM	NN	O
or	CC	O
50	CD	O
pM	NN	O
,	,	O
10	CD	O
pM	NN	O
or	CC	O
1	CD	O
pM	NNS	O
and	CC	O
all	DT	O
values	NNS	O
between	IN	O
these	DT	O
preferred	JJ	O
exemplary	JJ	O
points	NNS	O
.	.	O
Synagis®	NNP	O
,	,	O
a	DT	O
commercial	JJ	O
antibody	NN	O
directed	VBD	O
to	TO	O
the	DT	O
F	NNP	O
protein	NN	O
,	,	O
is	VBZ	O
established	VBN	O
to	TO	O
have	VB	O
an	DT	O
affinity	NN	O
of	IN	O
about	IN	O
5	CD	O
nM	NNS	O
.	.	O
A	DT	O
higher	JJR	O
affinity	NN	O
antibody	NN	O
against	IN	O
F	NNP	O
protein	NN	O
,	,	O
Numax™	NNP	O
(	(	O
motavizumab	NN	O
)	)	O
is	VBZ	O
estimated	VBN	O
to	TO	O
have	VB	O
an	DT	O
affinity	NN	O
of	IN	O
about	IN	O
50	CD	O
pM	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
show	NN	O
superior	JJ	O
ability	NN	O
to	TO	O
behave	VB	O
as	IN	O
therapeutics	NNS	O
,	,	O
and	CC	O
exhibit	VBZ	O
the	DT	O
capacity	NN	O
to	TO	O
lower	VB	O
the	DT	O
viral	JJ	O
count	NN	O
in	IN	O
lungs	NNS	O
at	IN	O
the	DT	O
peak	NN	O
of	IN	O
infection	NN	O
.	.	O
They	PRP	O
also	RB	O
exhibit	VBP	O
this	DT	O
ability	NN	O
at	IN	O
a	DT	O
point	NN	O
where	WRB	O
typically	RB	O
the	DT	O
infection	NN	O
has	VBZ	O
run	VBN	O
its	PRP$	O
course	NN	O
.	.	O
This	DT	O
is	VBZ	O
particularly	RB	O
useful	JJ	O
as	IN	O
subjects	NNS	O
recovering	VBG	O
from	IN	O
RSV	NNP	O
infection	NN	O
may	MD	O
continue	VB	O
to	TO	O
shed	VB	O
virus	NN	O
,	,	O
and	CC	O
thus	RB	O
be	VB	O
able	JJ	O
to	TO	O
infect	VB	O
others	NNS	O
in	IN	O
a	DT	O
post-clinical	JJ	O
setting	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
and	CC	O
fragments	NNS	O
thereof	NN	O
also	RB	O
treat	VBD	O
the	DT	O
symptoms	NNS	O
of	IN	O
infection	NN	O
,	,	O
including	VBG	O
inflammation	NN	O
in	IN	O
the	DT	O
lungs	NNS	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
been	VBN	O
obtained	VBN	O
in	IN	O
two	CD	O
exemplary	JJ	O
ways	NNS	O
.	.	O
In	IN	O
one	CD	O
approach	NN	O
,	,	O
an	DT	O
existing	VBG	O
monoclonal	JJ	O
antibody	NN	O
referenced	VBD	O
above	IN	O
,	,	O
131-2G	JJ	O
,	,	O
that	WDT	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
immunoreactive	JJ	O
with	IN	O
the	DT	O
conserved	JJ	O
region	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
,	,	O
was	VBD	O
first	RB	O
sequenced	VBN	O
and	CC	O
then	RB	O
humanized	VBN	O
by	IN	O
fusing	VBG	O
a	DT	O
human	JJ	O
constant	JJ	O
region	NN	O
with	IN	O
modified	JJ	O
human	JJ	O
variable	JJ	O
regions	NNS	O
(	(	O
both	DT	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
)	)	O
.	.	O
The	DT	O
variable	JJ	O
regions	NNS	O
were	VBD	O
chosen	VBN	O
based	VBN	O
on	IN	O
high	JJ	O
homology	NN	O
to	TO	O
the	DT	O
variable	JJ	O
regions	NNS	O
from	IN	O
the	DT	O
131-2G	JJ	O
antibody	NN	O
,	,	O
then	RB	O
modified	VBD	O
to	TO	O
incorporate	VB	O
the	DT	O
hypervariable	JJ	O
amino	NN	O
acids	NNS	O
from	IN	O
131-2G	JJ	O
.	.	O
The	DT	O
methods	NNS	O
for	IN	O
such	JJ	O
humanization	NN	O
are	VBP	O
generally	RB	O
known	VBN	O
provided	VBD	O
the	DT	O
correct	JJ	O
selection	NN	O
of	IN	O
amino	NN	O
acid	IN	O
replacements	NNS	O
can	MD	O
be	VB	O
determined	VBN	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
131-2G	JJ	O
,	,	O
the	DT	O
original	JJ	O
hybridoma	NN	O
line	NN	O
expressed	VBD	O
more	JJR	O
than	IN	O
one	CD	O
light	NN	O
chain	NN	O
,	,	O
requiring	VBG	O
determination	NN	O
of	IN	O
which	WDT	O
one	NN	O
was	VBD	O
in	IN	O
fact	NN	O
responsible	JJ	O
for	IN	O
binding	VBG	O
to	TO	O
the	DT	O
RSV	NNP	O
conserved	VBD	O
motif	NNS	O
.	.	O
This	DT	O
has	VBZ	O
been	VBN	O
determined	VBN	O
by	IN	O
the	DT	O
present	JJ	O
inventors	NNS	O
and	CC	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
exemplified	VBN	O
by	IN	O
the	DT	O
humanized	JJ	O
form	NN	O
of	IN	O
mAb	JJ	O
131-2G	JJ	O
.	.	O
In	IN	O
an	DT	O
alternative	JJ	O
method	NN	O
,	,	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
been	VBN	O
recovered	VBN	O
from	IN	O
RSV	NNP	O
exposed	VBD	O
human	JJ	O
donors	NNS	O
using	VBG	O
the	DT	O
proprietary	JJ	O
CellSpot™	NNP	O
method	NN	O
which	WDT	O
is	VBZ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,413,868	CD	O
,	,	O
PCT	NNP	O
publications	NNS	O
WO	NNP	O
2005/045396	CD	O
and	CC	O
WO	NNP	O
2008/008858	CD	O
,	,	O
all	DT	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
In	IN	O
this	DT	O
method	NN	O
,	,	O
40	CD	O
RSV-infected	JJ	O
donor	NN	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
,	,	O
in	IN	O
a	DT	O
process	NN	O
yielding	VBG	O
˜500,000	CD	O
antibody-producing	JJ	O
cells	NNS	O
per	IN	O
blood	NN	O
sample	NN	O
.	.	O
Thus	RB	O
,	,	O
in	IN	O
total	JJ	O
,	,	O
there	EX	O
were	VBD	O
˜20,000,000	CD	O
different	JJ	O
B	NNP	O
cells	NNS	O
analyzed	VBD	O
for	IN	O
production	NN	O
of	IN	O
antibodies	NNS	O
which	WDT	O
are	VBP	O
specific	JJ	O
to	TO	O
the	DT	O
conserved	JJ	O
region	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
.	.	O
Only	RB	O
˜10	CD	O
%	NN	O
of	IN	O
the	DT	O
donors	NNS	O
had	VBD	O
a	DT	O
useful	JJ	O
frequency	NN	O
of	IN	O
Ga/Gb	NNP	O
specific	JJ	O
clones	NNS	O
(	(	O
i.e.	FW	O
,	,	O
strain	VB	O
independent	JJ	O
)	)	O
,	,	O
and	CC	O
such	JJ	O
clones	NNS	O
were	VBD	O
only	RB	O
present	JJ	O
at	IN	O
˜1/50,000	NNP	O
cells	NNS	O
even	RB	O
in	IN	O
the	DT	O
highest	JJS	O
frequency	NN	O
specimens	NNS	O
.	.	O
Overall	JJ	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
the	DT	O
desired	JJ	O
cells	NNS	O
was	VBD	O
˜0.003	JJ	O
%	NN	O
,	,	O
which	WDT	O
is	VBZ	O
low	JJ	O
enough	RB	O
to	TO	O
be	VB	O
impractical	JJ	O
to	TO	O
recover	VB	O
by	IN	O
standard	JJ	O
methods	NNS	O
but	CC	O
readily	RB	O
accessible	JJ	O
using	VBG	O
CellSpot™	NNP	O
.	.	O
FIG	NNP	O
.	.	O
1	CD	O
shows	VBZ	O
the	DT	O
spectrum	NN	O
of	IN	O
reactivities	NNS	O
to	TO	O
RSV	NNP	O
antigens	NNS	O
for	IN	O
24	CD	O
donors	NNS	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
this	DT	O
figure	NN	O
,	,	O
even	RB	O
in	IN	O
those	DT	O
individuals	NNS	O
where	WRB	O
antibodies	NNS	O
crossreacting	VBG	O
with	IN	O
both	DT	O
A	NNP	O
and	CC	O
B	NNP	O
strain-derived	JJ	O
G	NNP	O
protein	NN	O
were	VBD	O
found	VBN	O
,	,	O
the	DT	O
prevalence	NN	O
of	IN	O
these	DT	O
antibodies	NNS	O
is	VBZ	O
much	RB	O
smaller	JJR	O
than	IN	O
that	DT	O
of	IN	O
antibodies	NNS	O
immunoreactive	VBP	O
with	IN	O
F	NNP	O
protein	NN	O
or	CC	O
with	IN	O
Ga	NNP	O
or	CC	O
Gb	NNP	O
alone	RB	O
.	.	O
A	DT	O
surprisingly	RB	O
large	JJ	O
number	NN	O
of	IN	O
clones	NNS	O
recognized	VBN	O
both	PDT	O
the	DT	O
F	NNP	O
and	CC	O
G	NNP	O
protein	NN	O
(	(	O
denoted	VBN	O
“	NNP	O
mix	NNP	O
”	NNP	O
)	)	O
,	,	O
which	WDT	O
are	VBP	O
likely	JJ	O
recognizing	VBG	O
shared	VBN	O
carbohydrate	JJ	O
determinants	NNS	O
.	.	O
Affinities	NNS	O
of	IN	O
such	JJ	O
anti-carbohydrate	JJ	O
antibodies	NNS	O
are	VBP	O
typically	RB	O
poor	JJ	O
and	CC	O
were	VBD	O
excluded	VBN	O
from	IN	O
further	JJ	O
consideration	NN	O
.	.	O
The	DT	O
highest	JJS	O
affinity	NN	O
antibody	NN	O
found	VBD	O
within	IN	O
this	DT	O
cohort	NN	O
of	IN	O
donors	NNS	O
,	,	O
with	IN	O
an	DT	O
affinity	NN	O
of	IN	O
1	CD	O
pM	NN	O
,	,	O
came	VBD	O
from	IN	O
one	CD	O
of	IN	O
the	DT	O
donors	NNS	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
frequency	NN	O
of	IN	O
Ga/Gb	NNP	O
specific	JJ	O
clones	NNS	O
,	,	O
˜1	NNP	O
ppm	NN	O
.	.	O
That	DT	O
is	VBZ	O
,	,	O
finding	VBG	O
this	DT	O
highly	RB	O
favorable	JJ	O
clone	NN	O
would	MD	O
have	VB	O
been	VBN	O
unlikely	RB	O
without	IN	O
comprehensive	JJ	O
screening	NN	O
of	IN	O
the	DT	O
full	JJ	O
repertoire	NN	O
from	IN	O
all	DT	O
donors	NNS	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
perform	VB	O
this	DT	O
screen	NN	O
,	,	O
B	NNP	O
cells	NNS	O
were	VBD	O
immortalized	VBN	O
with	IN	O
Epstein-Barr	NNP	O
Virus	NNP	O
and	CC	O
assessed	VBD	O
according	VBG	O
to	TO	O
the	DT	O
above-described	JJ	O
methods	NNS	O
(	(	O
see	VB	O
Example	NNP	O
2	CD	O
for	IN	O
details	NNS	O
)	)	O
.	.	O
Successful	JJ	O
B	NNP	O
cells	NNS	O
were	VBD	O
identified	VBN	O
and	CC	O
the	DT	O
nucleotide	JJ	O
sequences	NNS	O
encoding	VBG	O
the	DT	O
identified	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
were	VBD	O
obtained	VBN	O
and	CC	O
sequenced	VBN	O
.	.	O
These	DT	O
were	VBD	O
then	RB	O
manipulated	VBN	O
recombinantly	RB	O
to	TO	O
produce	VB	O
antibodies	NNS	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
line	NN	O
.	.	O
An	DT	O
important	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
function	NN	O
resides	NNS	O
in	IN	O
a	DT	O
secreted	JJ	O
form	NN	O
of	IN	O
the	DT	O
protein	NN	O
,	,	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
,	,	O
created	VBN	O
by	IN	O
an	DT	O
alternative	JJ	O
splice	NN	O
site	NN	O
near	IN	O
residue	JJ	O
50	CD	O
.	.	O
Engineering	VBG	O
virus	NN	O
to	TO	O
lack	VB	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
resulted	VBD	O
in	IN	O
reduced	JJ	O
level	NN	O
of	IN	O
pulmonary	JJ	O
infiltrating	NN	O
cells	NNS	O
(	(	O
Maher	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Microbes	NNP	I
Infect	NNP	I
.	.	I
(	(	I
2004	CD	I
)	)	I
6:1049-1055	NN	I
)	)	O
.	.	O
Conversely	RB	O
,	,	O
priming	VBG	O
mice	NN	O
with	IN	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
augments	VBZ	O
IL-5	JJ	O
production	NN	O
and	CC	O
lung	NN	O
eosinophilia	NNS	O
(	(	O
Johnson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
(	(	I
1998	CD	I
)	)	I
72:2871-2880	CD	I
)	)	O
.	.	O
Accordingly	RB	O
,	,	O
suppressing	VBG	O
the	DT	O
activity	NN	O
of	IN	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
is	VBZ	O
important	JJ	O
for	IN	O
effective	JJ	O
treatment	NN	O
of	IN	O
RSV	NNP	O
.	.	O
Achieving	VBG	O
that	DT	O
goal	NN	O
requires	VBZ	O
a	DT	O
high	JJ	O
affinity	NN	O
antibody	NN	O
,	,	O
as	IN	O
is	VBZ	O
generally	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
e.g.	JJ	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,083,950	CD	O
)	)	O
.	.	O
Since	IN	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
is	VBZ	O
specifically	RB	O
implicated	VBN	O
in	IN	O
the	DT	O
function	NN	O
of	IN	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
as	IN	O
an	DT	O
immuno-modulatory	JJ	O
agent	NN	O
,	,	O
an	DT	O
effective	JJ	O
antibody	NN	O
against	IN	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
should	MD	O
target	VB	O
this	DT	O
motif	NN	O
.	.	O
Our	PRP$	O
survey	NN	O
of	IN	O
the	DT	O
human	JJ	O
B	NNP	O
cell	NN	O
repertoire	NN	O
from	IN	O
RSV	NNP	O
exposed	VBD	O
subjects	NNS	O
was	VBD	O
unbiased	VBN	O
in	IN	O
its	PRP$	O
search	NN	O
for	IN	O
antibodies	NNS	O
that	WDT	O
bind	VBP	O
to	TO	O
the	DT	O
G	NNP	O
protein	NN	O
from	IN	O
both	DT	O
strains	NNS	O
A	DT	O
and	CC	O
B	NNP	O
(	(	O
Ga/Gb	NNP	O
cross-reactive	JJ	O
antibodies	NNS	O
)	)	O
.	.	O
Because	IN	O
the	DT	O
survey	NN	O
was	VBD	O
comprehensive	JJ	O
(	(	O
40	CD	O
subjects	NNS	O
,	,	O
˜500,000	NN	O
B	NNP	O
cells	NNS	O
examined	VBD	O
from	IN	O
each	DT	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
a	DT	O
striking	JJ	O
finding	NN	O
that	IN	O
all	DT	O
of	IN	O
the	DT	O
Ga/Gb	NNP	O
cross-reactive	JJ	O
antibodies	NNS	O
binding	VBG	O
linear	JJ	O
epitopes	NNS	O
suitable	JJ	O
for	IN	O
mapping	VBG	O
recognize	NN	O
epitopes	NNS	O
within	IN	O
a	DT	O
few	JJ	O
residues	NNS	O
of	IN	O
each	DT	O
other	JJ	O
,	,	O
within	IN	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
.	.	O
This	DT	O
region	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
poorly	RB	O
immunogenic	JJ	O
,	,	O
as	IN	O
summarized	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
2B	CD	O
(	(	O
Plotnicky-Gilquin	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
(	(	I
2002	CD	I
)	)	I
303:130-137	CD	I
)	)	O
,	,	O
consistent	JJ	O
with	IN	O
the	DT	O
low	JJ	O
frequency	NN	O
of	IN	O
high	JJ	O
affinity	NN	O
clones	NNS	O
to	TO	O
this	DT	O
region	NN	O
reported	VBD	O
here	RB	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
characterized	VBN	O
this	DT	O
region	NN	O
by	IN	O
examining	VBG	O
the	DT	O
published	VBN	O
sequences	NNS	O
of	IN	O
G	NNP	O
proteins	NNS	O
from	IN	O
>	JJ	O
75	CD	O
RSV	NNP	O
isolates	NNS	O
.	.	O
Most	JJS	O
residues	NNS	O
of	IN	O
the	DT	O
protein	NN	O
show	VB	O
several	JJ	O
to	TO	O
many	JJ	O
polymorphisms	NNS	O
in	IN	O
the	DT	O
collection	NN	O
.	.	O
Two	CD	O
regions	NNS	O
are	VBP	O
strikingly	RB	O
free	JJ	O
of	IN	O
polymorphisms	NNS	O
:	:	O
the	DT	O
alternative	JJ	O
splice	NN	O
site	NN	O
that	WDT	O
creates	VBZ	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
and	CC	O
the	DT	O
central	JJ	O
conserved	JJ	O
region	NN	O
to	TO	O
which	WDT	O
all	DT	O
Ga/Gb	NNP	O
cross-reactive	JJ	O
antibodies	NNS	O
bind	IN	O
(	(	O
FIG	NNP	O
.	.	O
2C	CD	O
)	)	O
.	.	O
That	DT	O
is	VBZ	O
,	,	O
we	PRP	O
have	VBP	O
discovered	VBN	O
that	IN	O
a	DT	O
region	NN	O
which	WDT	O
is	VBZ	O
highly	RB	O
conserved	VBN	O
,	,	O
indicating	VBG	O
critical	JJ	O
functionality	NN	O
,	,	O
is	VBZ	O
also	RB	O
poorly	RB	O
immunogenic	JJ	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
mechanisms	NNS	O
may	MD	O
account	VB	O
for	IN	O
that	DT	O
poor	JJ	O
immunogenicity	NN	O
,	,	O
for	IN	O
example	NN	O
absence	NN	O
of	IN	O
nearby	JJ	O
proteolytic	JJ	O
cleavage	NN	O
sites	NNS	O
suitable	JJ	O
for	IN	O
effectively	RB	O
presenting	VBG	O
the	DT	O
region	NN	O
in	IN	O
combination	NN	O
with	IN	O
histocompatibility	NN	O
antigens	NNS	O
for	IN	O
display	NN	O
to	TO	O
the	DT	O
rest	NN	O
of	IN	O
the	DT	O
immune	NN	O
system	NN	O
.	.	O
Whatever	WDT	O
the	DT	O
mechanism	NN	O
,	,	O
this	DT	O
surprising	JJ	O
result	NN	O
is	VBZ	O
clear	JJ	O
:	:	O
those	DT	O
viruses	NNS	O
that	WDT	O
have	VBP	O
survived	VBN	O
show	VBP	O
low	JJ	O
immunogenicity	NN	O
to	TO	O
this	DT	O
region	NN	O
.	.	O
We	PRP	O
therefore	RB	O
predicted	VBD	O
that	IN	O
augmenting	VBG	O
the	DT	O
immune	NN	O
system	NN	O
's	POS	O
activity	NN	O
against	IN	O
this	DT	O
region	NN	O
,	,	O
by	IN	O
passive	JJ	O
transfer	NN	O
of	IN	O
suitable	JJ	O
antibodies	NNS	O
,	,	O
would	MD	O
be	VB	O
efficacious	JJ	O
,	,	O
and	CC	O
this	DT	O
has	VBZ	O
proven	VBN	O
to	TO	O
be	VB	O
the	DT	O
case	NN	O
in	IN	O
our	PRP$	O
animal	JJ	O
models	NNS	O
.	.	O
The	DT	O
alternative	JJ	O
splice	NN	O
site	NN	O
,	,	O
although	IN	O
equally	RB	O
conserved	VBN	O
,	,	O
is	VBZ	O
not	RB	O
unusually	RB	O
low	JJ	O
in	IN	O
immunogenicity	NN	O
suggesting	NN	O
that	IN	O
its	PRP$	O
importance	NN	O
is	VBZ	O
only	RB	O
with	IN	O
regard	NN	O
to	TO	O
creation	NN	O
of	IN	O
s	NN	O
(	(	O
G	NNP	O
)	)	O
,	,	O
thus	RB	O
making	VBG	O
it	PRP	O
a	DT	O
poor	JJ	O
target	NN	O
for	IN	O
passive	JJ	O
immunotherapy	NN	O
.	.	O
Production	NN	O
of	IN	O
the	DT	O
human	JJ	O
or	CC	O
humanized	VBN	O
antibody	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
conventional	JJ	O
recombinant	NN	O
techniques	NNS	O
,	,	O
such	JJ	O
as	IN	O
production	NN	O
in	IN	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
cells	NNS	O
or	CC	O
other	JJ	O
eukaryotic	JJ	O
cell	NN	O
lines	NNS	O
,	,	O
such	JJ	O
as	IN	O
insect	JJ	O
cells	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
techniques	NNS	O
are	VBP	O
also	RB	O
known	VBN	O
for	IN	O
producing	VBG	O
recombinant	JJ	O
materials	NNS	O
,	,	O
including	VBG	O
antibodies	NNS	O
,	,	O
in	IN	O
plants	NNS	O
and	CC	O
in	IN	O
transgenic	JJ	O
animals	NNS	O
,	,	O
for	IN	O
example	NN	O
in	IN	O
the	DT	O
milk	NN	O
of	IN	O
bovines	NNS	O
,	,	O
or	CC	O
in	IN	O
microbial	JJ	O
or	CC	O
plant	NN	O
or	CC	O
insect	VB	O
derived	VBN	O
single	JJ	O
cell	NN	O
systems	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
since	IN	O
the	DT	O
nucleotide	JJ	O
sequences	NNS	O
encoding	VBG	O
the	DT	O
antibodies	NNS	O
are	VBP	O
available	JJ	O
,	,	O
the	DT	O
relevant	NN	O
fragments	NNS	O
which	WDT	O
bind	VBP	O
the	DT	O
same	JJ	O
epitope	NN	O
,	,	O
e.g.	NN	O
,	,	O
Fab	NNP	O
,	,	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
or	CC	O
Fv	NNP	O
fragments	NNS	O
,	,	O
may	MD	O
be	VB	O
produced	VBN	O
recombinantly	RB	O
(	(	O
or	CC	O
by	IN	O
proteolytic	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
protein	NN	O
itself	PRP	O
)	)	O
and	CC	O
the	DT	O
antibody	NN	O
may	MD	O
be	VB	O
produced	VBN	O
in	IN	O
single-chain	JJ	O
form	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
techniques	NNS	O
for	IN	O
manipulation	NN	O
of	IN	O
recombinant	JJ	O
antibody	NN	O
production	NN	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
use	NN	O
in	IN	O
therapy	NN	O
,	,	O
the	DT	O
recombinantly	RB	O
produced	VBN	O
antibodies	NNS	O
or	CC	O
fragments	NNS	O
are	VBP	O
formulated	VBN	O
into	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
using	VBG	O
suitable	JJ	O
excipients	NNS	O
and	CC	O
administered	VBD	O
according	VBG	O
to	TO	O
standard	JJ	O
protocols	NNS	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
may	MD	O
have	VB	O
as	IN	O
their	PRP$	O
sole	JJ	O
active	JJ	O
ingredient	NN	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
or	CC	O
fragment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
especially	RB	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
or	CC	O
fragment	NN	O
that	WDT	O
is	VBZ	O
crossreactive	JJ	O
with	IN	O
G	NNP	O
protein	NN	O
of	IN	O
both	CC	O
A	NNP	O
and	CC	O
B	NNP	O
strains	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
two	CD	O
monoclonal	JJ	O
antibodies	NNS	O
may	MD	O
be	VB	O
the	DT	O
sole	JJ	O
active	JJ	O
ingredients	NNS	O
wherein	VBP	O
one	CD	O
more	JJR	O
strongly	RB	O
reacts	VBZ	O
with	IN	O
the	DT	O
A	NNP	O
strain	NN	O
G	NNP	O
protein	NN	O
and	CC	O
the	DT	O
other	JJ	O
more	JJR	O
strongly	RB	O
with	IN	O
the	DT	O
B	NNP	O
strain	NN	O
G	NNP	O
protein	NN	O
.	.	O
In	IN	O
all	DT	O
of	IN	O
these	DT	O
cases	NNS	O
,	,	O
additional	JJ	O
therapeutic	JJ	O
agents	NNS	O
may	MD	O
be	VB	O
present	JJ	O
,	,	O
including	VBG	O
one	CD	O
or	CC	O
more	JJR	O
antibodies	NNS	O
that	WDT	O
is	VBZ	O
immunoreactive	JJ	O
with	IN	O
the	DT	O
F	NNP	O
protein	NN	O
or	CC	O
other	JJ	O
therapeutic	JJ	O
agents	NNS	O
that	WDT	O
are	VBP	O
effective	JJ	O
against	IN	O
RSV	NNP	O
or	CC	O
inflammation	NN	O
.	.	O
Thus	RB	O
,	,	O
anti-inflammatories	NNS	O
such	JJ	O
as	IN	O
both	DT	O
steroidal	JJ	O
and	CC	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
compounds	NNS	O
may	MD	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
compositions	NNS	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
compounds	NNS	O
may	MD	O
include	VB	O
nutritional	JJ	O
substances	NNS	O
such	JJ	O
as	IN	O
vitamins	NNS	O
,	,	O
or	CC	O
any	DT	O
other	JJ	O
beneficial	JJ	O
compound	NN	O
other	JJ	O
than	IN	O
an	DT	O
antibody	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
when	WRB	O
the	DT	O
formulations	NNS	O
for	IN	O
administration	NN	O
are	VBP	O
used	VBN	O
in	IN	O
order	NN	O
to	TO	O
increase	VB	O
resistance	NN	O
to	TO	O
infection	NN	O
,	,	O
complete	JJ	O
antibodies	NNS	O
,	,	O
including	VBG	O
the	DT	O
complement-containing	JJ	O
Fc	NNP	O
region	NN	O
are	VBP	O
employed	VBN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
antibodies	NNS	O
are	VBP	O
administered	VBN	O
as	IN	O
dosage	NN	O
levels	NNS	O
of	IN	O
0.01-20	JJ	O
mg/kg	NN	O
of	IN	O
human	JJ	O
subjects	NNS	O
or	CC	O
in	IN	O
amounts	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
0.01-5	JJ	O
mg/kg	NN	O
or	CC	O
intermediate	JJ	O
amounts	NNS	O
within	IN	O
these	DT	O
ranges	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
amounts	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
0.1-1.0	JJ	O
mg/kg	NNS	O
are	VBP	O
employed	VBN	O
.	.	O
Repeated	VBN	O
administration	NN	O
separated	VBN	O
by	IN	O
several	JJ	O
days	NNS	O
or	CC	O
several	JJ	O
weeks	NNS	O
or	CC	O
several	JJ	O
months	NNS	O
may	MD	O
be	VB	O
beneficial	JJ	O
.	.	O
Boosters	NNS	O
may	MD	O
also	RB	O
be	VB	O
offered	VBN	O
after	IN	O
one	CD	O
or	CC	O
two	CD	O
or	CC	O
five	CD	O
or	CC	O
ten	CD	O
years	NNS	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
for	IN	O
a	DT	O
therapeutic	JJ	O
effect	NN	O
in	IN	O
order	NN	O
to	TO	O
reduce	VB	O
viral	JJ	O
load	NN	O
,	,	O
complete	JJ	O
antibodies	NNS	O
,	,	O
containing	VBG	O
the	DT	O
complement-containing	JJ	O
Fc	NNP	O
region	NN	O
are	VBP	O
also	RB	O
employed	VBN	O
.	.	O
The	DT	O
amounts	NNS	O
administered	VBN	O
in	IN	O
such	JJ	O
protocols	NNS	O
are	VBP	O
of	IN	O
the	DT	O
order	NN	O
of	IN	O
0.001-50	JJ	O
mg/kg	NN	O
or	CC	O
intermediate	JJ	O
values	NNS	O
in	IN	O
this	DT	O
range	NN	O
such	JJ	O
as	IN	O
0.01	CD	O
,	,	O
1	CD	O
or	CC	O
10	CD	O
mg/kg	NNS	O
are	VBP	O
employed	VBN	O
.	.	O
Repeated	VBN	O
administration	NN	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
.	.	O
The	DT	O
therapeutic	JJ	O
treatment	NN	O
is	VBZ	O
administered	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
diagnosis	NN	O
of	IN	O
infection	NN	O
,	,	O
although	IN	O
administration	NN	O
within	IN	O
a	DT	O
few	JJ	O
days	NNS	O
is	VBZ	O
also	RB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Repeated	VBN	O
administration	NN	O
may	MD	O
also	RB	O
be	VB	O
employed	VBN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
inflammatory	NN	O
response	NN	O
in	IN	O
the	DT	O
lungs	NNS	O
,	,	O
only	RB	O
the	DT	O
immunospecific	JJ	O
fragments	NNS	O
of	IN	O
the	DT	O
antibodies	NNS	O
need	VBP	O
be	VB	O
employed	VBN	O
.	.	O
Dosage	NN	O
levels	NNS	O
are	VBP	O
similar	JJ	O
to	TO	O
those	DT	O
for	IN	O
whole	JJ	O
antibodies	NNS	O
.	.	O
Administration	NN	O
of	IN	O
mixtures	NNS	O
of	IN	O
immunospecific	JJ	O
fragments	NNS	O
and	CC	O
entire	JJ	O
antibodies	NNS	O
is	VBZ	O
also	RB	O
included	VBN	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Administration	NN	O
of	IN	O
the	DT	O
antibody	NN	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
typically	RB	O
by	IN	O
injection	NN	O
,	,	O
generally	RB	O
intravenous	JJ	O
injection	NN	O
.	.	O
Thus	RB	O
,	,	O
parenteral	JJ	O
administration	NN	O
is	VBZ	O
preferred	VBN	O
.	.	O
However	RB	O
,	,	O
any	DT	O
workable	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
included	VBN	O
.	.	O
The	DT	O
formulations	NNS	O
are	VBP	O
prepared	VBN	O
in	IN	O
ways	NNS	O
generally	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
administering	VBG	O
antibody	NN	O
compositions	NNS	O
.	.	O
Suitable	JJ	O
formulations	NNS	O
may	MD	O
be	VB	O
found	VBN	O
in	IN	O
standard	JJ	O
formularies	NNS	O
,	,	O
such	JJ	O
as	IN	O
Remington	NNP	B
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
latest	JJS	I
edition	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
The	DT	O
formulations	NNS	O
are	VBP	O
typically	RB	O
those	DT	O
suitable	JJ	O
for	IN	O
parenteral	JJ	O
administration	NN	O
including	VBG	O
isotonic	JJ	O
solutions	NNS	O
,	,	O
which	WDT	O
include	VBP	O
buffers	NNS	O
,	,	O
antioxidants	NNS	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
emulsions	NNS	O
that	WDT	O
include	VBP	O
delivery	NN	O
vehicles	NNS	O
such	JJ	O
as	IN	O
liposomes	NNS	O
,	,	O
micelles	NNS	O
and	CC	O
nanoparticles	NNS	O
.	.	O
The	DT	O
desired	JJ	O
protocols	NNS	O
and	CC	O
formulations	NNS	O
are	VBP	O
dependent	JJ	O
on	IN	O
the	DT	O
judgment	NN	O
of	IN	O
the	DT	O
attending	VBG	O
practitioner	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
specific	JJ	O
condition	NN	O
of	IN	O
the	DT	O
subject	NN	O
.	.	O
Dosage	NN	O
levels	NNS	O
will	MD	O
depend	VB	O
on	IN	O
the	DT	O
age	NN	O
,	,	O
general	JJ	O
health	NN	O
and	CC	O
severity	NN	O
of	IN	O
infection	NN	O
,	,	O
if	IN	O
appropriate	JJ	O
,	,	O
of	IN	O
the	DT	O
subject	NN	O
.	.	O
The	DT	O
following	JJ	O
examples	NNS	O
are	VBP	O
offered	VBN	O
to	TO	O
illustrate	VB	O
but	CC	O
not	RB	O
to	TO	O
limit	VB	O
the	DT	O
invention	NN	O
.	.	O
Example	RB	O
1	CD	O
Cloning	NNP	O
and	CC	O
Humanization	NNP	O
of	IN	O
131-2G	JJ	O
Cloning	NNP	O
and	CC	O
sequencing	NN	O
of	IN	O
mAb	JJ	O
131-2G	JJ	O
.	.	O
Total	JJ	O
mRNA	NN	O
was	VBD	O
extracted	VBN	O
from	IN	O
131-2G	JJ	O
hybridoma	NN	O
according	VBG	O
to	TO	O
the	DT	O
manufacturer	NN	O
's	POS	O
directions	NNS	O
(	(	O
RNeasy™	NNP	O
kit	NN	O
:	:	O
Qiagen	NN	O
Santa	NNP	O
Clarita	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Seven	RB	O
family-specific	JJ	O
5′	CD	O
VγFR1	NNP	O
primers	NNS	O
designed	VBN	O
to	TO	O
target	VB	O
the	DT	O
VH1	NNP	O
through	IN	O
VH7	NNP	O
gene	NN	O
families	NNS	O
of	IN	O
Igγ	NNP	O
,	,	O
and	CC	O
one	CD	O
consensus	NN	O
3′	CD	O
Cγ1	NNP	O
primer	NN	O
were	VBD	O
used	VBN	O
to	TO	O
amplify	VB	O
and	CC	O
sequence	VB	O
the	DT	O
variable	JJ	O
region	NN	O
of	IN	O
131-2G	JJ	O
heavy	JJ	O
chain	NN	O
.	.	O
One	CD	O
consensus	NN	O
5′	CD	O
Vk	NNP	O
primer	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
amplify	VB	O
each	DT	O
of	IN	O
the	DT	O
Vk	NNP	O
families	NNS	O
,	,	O
and	CC	O
one	CD	O
reverse	NN	O
primer	NN	O
specific	NN	O
to	TO	O
the	DT	O
kappa	NN	O
constant	JJ	O
region	NN	O
were	VBD	O
used	VBN	O
to	TO	O
amplify	VB	O
and	CC	O
sequence	VB	O
the	DT	O
kappa	NN	O
light	NN	O
chain	NN	O
.	.	O
The	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
transcripts	NNS	O
were	VBD	O
amplified	VBN	O
from	IN	O
100	CD	O
ng	JJ	O
total	JJ	O
RNA	NNP	O
using	VBG	O
reverse	JJ	O
transcriptase	NN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
RT-PCR	NNP	O
)	)	O
.	.	O
Two	CD	O
PCR	NNP	O
reactions	NNS	O
were	VBD	O
run	VBN	O
for	IN	O
the	DT	O
131-2G	JJ	O
hybridoma	NN	O
:	:	O
one	CD	O
for	IN	O
light	NN	O
chain	NN	O
kappa	NN	O
(	(	O
κ	NNP	O
)	)	O
and	CC	O
one	CD	O
for	IN	O
gamma	NN	O
heavy	NN	O
chain	NN	O
(	(	O
γ1	NNP	O
)	)	O
.	.	O
The	DT	O
QIAGEN®	NNP	O
OneStep	NNP	O
RT-PCR	NNP	O
kit	NN	O
was	VBD	O
used	VBN	O
for	IN	O
amplification	NN	O
,	,	O
(	(	O
Qiagen	NNP	O
Catalog	NNP	O
No	NNP	O
.	.	O
210212	CD	O
)	)	O
.	.	O
The	DT	O
extracted	JJ	O
PCR	NNP	O
products	NNS	O
were	VBD	O
directly	RB	O
sequenced	VBN	O
using	VBG	O
specific	JJ	O
constant	JJ	O
region	NN	O
primers	NNS	O
.	.	O
The	DT	O
derived	JJ	O
sequences	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
known	VB	O
germline	JJ	O
DNA	NNP	O
sequences	NNS	O
of	IN	O
the	DT	O
Ig	NNP	O
V-	NNP	O
and	CC	O
J-regions	NNP	O
using	VBG	O
the	DT	O
V-BASE2	NNP	O
and	CC	O
by	IN	O
alignment	NN	O
of	IN	O
VH	NNP	O
and	CC	O
VL	NNP	O
genes	NNS	O
to	TO	O
the	DT	O
mouse	NN	O
germ	JJ	O
line	NN	O
database	NN	O
.	.	O
Sequence	NN	O
analysis	NN	O
:	:	O
from	IN	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
information	NN	O
,	,	O
data	NN	O
regarding	NN	O
V	NNP	O
and	CC	O
J	NNP	O
gene	NN	O
segment	NN	O
of	IN	O
the	DT	O
heavy	JJ	O
and	CC	O
light	JJ	O
chain	NN	O
of	IN	O
131-2G	JJ	O
were	VBD	O
obtained	VBN	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
sequence	NN	O
data	VBD	O
new	JJ	O
primer	NN	O
sets	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
leader	NN	O
sequence	NN	O
of	IN	O
the	DT	O
Ig	NNP	O
VH	NNP	O
and	CC	O
VK	NNP	O
chain	NN	O
of	IN	O
131-2G	JJ	O
were	VBD	O
designed	VBN	O
.	.	O
V	NNP	O
gene	NN	O
usage	NN	O
and	CC	O
sequence	NN	O
analysis	NN	O
:	:	O
Heavy	NNP	O
chain	NN	O
genes	NNS	O
of	IN	O
13-12G	NNS	O
were	VBD	O
from	IN	O
the	DT	O
VH1	NNP	O
germline	NN	O
gene	NN	O
family	NN	O
,	,	O
the	DT	O
germline	NN	O
gene	NN	O
for	IN	O
the	DT	O
D	NNP	O
region	NN	O
is	VBZ	O
DSP2.2	NNP	O
and	CC	O
the	DT	O
J	NNP	O
region	NN	O
was	VBD	O
from	IN	O
the	DT	O
JH3	NNP	O
germline	NN	O
.	.	O
Light	NNP	O
chain	NN	O
genes	NNS	O
were	VBD	O
from	IN	O
Vkappa	NNP	O
1	CD	O
(	(	O
K1A5	NNP	O
)	)	O
and	CC	O
Jkappa4	NNP	O
,	,	O
germline	JJ	O
gene	NN	O
families	NNS	O
.	.	O
131-2G	JJ	O
Uses	VBZ	O
a	DT	O
V	NNP	O
Segment	NNP	O
of	IN	O
the	DT	O
IgH-VJ558	NNP	O
VH1	NNP	O
Family	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:4-5	NNP	O
)	)	O
:	:	O
131-2G	JJ	O
Uses	VBZ	O
a	DT	O
V	NNP	O
Segment	NNP	O
of	IN	O
the	DT	O
IgKV1	NNP	O
Subgroup	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:6-7	NNP	O
)	)	O
:	:	O
Humanization	NN	O
of	IN	O
mAb	JJ	O
131-2G	JJ	O
.	.	O
The	DT	O
binding	NN	O
of	IN	O
an	DT	O
Antibody	NNP	O
(	(	O
Ab	NNP	O
)	)	O
to	TO	O
its	PRP$	O
cognate	NN	O
Antigen	NNP	O
(	(	O
Ag	NNP	O
)	)	O
is	VBZ	O
a	DT	O
highly	RB	O
specific	JJ	O
interaction	NN	O
.	.	O
This	DT	O
specificity	NN	O
resides	VBZ	O
in	IN	O
the	DT	O
structural	JJ	O
complementarity	NN	O
between	IN	O
the	DT	O
Ab-combining	NNP	O
site	NN	O
and	CC	O
the	DT	O
antigenic	JJ	O
determinant	NN	O
.	.	O
Ab-combining	JJ	O
sites	NNS	O
are	VBP	O
made	VBN	O
up	IN	O
of	IN	O
residues	NNS	O
that	WDT	O
are	VBP	O
primarily	RB	O
from	IN	O
the	DT	O
hypervariable	JJ	O
or	CC	O
complementarity	NN	O
determining	VBG	O
regions	NNS	O
(	(	O
CDRs	NNP	O
)	)	O
;	:	O
occasionally	RB	O
,	,	O
residues	NNS	O
from	IN	O
non-hypervariable	JJ	O
(	(	O
or	CC	O
framework	NN	O
)	)	O
regions	NNS	O
influence	VBP	O
the	DT	O
overall	JJ	O
domain	NN	O
structure	NN	O
and	CC	O
,	,	O
hence	RB	O
,	,	O
the	DT	O
combining	VBG	O
site	NN	O
.	.	O
The	DT	O
mouse	NN	O
VH	NNP	O
gene	NN	O
segment	NN	O
repertoire	NN	O
is	VBZ	O
twice	RB	O
the	DT	O
size	NN	O
of	IN	O
that	DT	O
in	IN	O
humans	NNS	O
and	CC	O
contains	VBZ	O
more	RBR	O
functional	JJ	O
genes	NNS	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
human	JJ	O
IgH	NNP	O
locus	NN	O
.	.	O
The	DT	O
mouse	NN	O
and	CC	O
the	DT	O
human	JJ	O
loci	NN	O
bear	IN	O
no	DT	O
large-scale	JJ	O
similarity	NN	O
to	TO	O
each	DT	O
other	JJ	O
.	.	O
The	DT	O
first	JJ	O
two	CD	O
CDRs	NNP	O
of	IN	O
VH	NNP	O
and	CC	O
VL	NNP	O
domains	NNS	O
have	VBP	O
a	DT	O
small	JJ	O
repertoire	NN	O
structure	NN	O
of	IN	O
main	JJ	O
chain	NN	O
conformation	NN	O
known	VBN	O
as	IN	O
the	DT	O
canonical	JJ	O
structures	NNS	O
.	.	O
The	DT	O
existence	NN	O
of	IN	O
a	DT	O
particular	JJ	O
canonical	JJ	O
structure	NN	O
is	VBZ	O
mainly	RB	O
determined	VBN	O
by	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
CDRs	NNP	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
key	JJ	O
residues	NNS	O
at	IN	O
particular	JJ	O
sites	NNS	O
in	IN	O
the	DT	O
sequence	NN	O
.	.	O
The	DT	O
same	JJ	O
canonical	JJ	O
structure	NN	O
combinations	NNS	O
of	IN	O
VH1	NNP	O
family	NN	O
(	(	O
VH1	NNP	O
1-2	CD	O
)	)	O
are	VBP	O
shared	VBN	O
between	IN	O
the	DT	O
members	NNS	O
of	IN	O
human	JJ	O
VH1	NNP	O
and	CC	O
mouse	VB	O
VH1	NNP	O
families	NNS	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
sequence	NN	O
analysis	NN	O
of	IN	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
of	IN	O
131-2G	JJ	O
and	CC	O
the	DT	O
fact	NN	O
that	IN	O
131-2G	JJ	O
uses	NNS	O
V	NNP	O
segments	NNS	O
of	IN	O
IgH-VJ558	NNP	O
VH1	NNP	O
family	NN	O
and	CC	O
Igκ1	NNP	O
family	NN	O
,	,	O
both	DT	O
chains	NNS	O
were	VBD	O
aligned	VBN	O
and	CC	O
compared	VBN	O
to	TO	O
the	DT	O
members	NNS	O
of	IN	O
the	DT	O
human	JJ	O
VH1	NNP	O
and	CC	O
VK1	NNP	O
families	NNS	O
.	.	O
Sequence	NNP	O
homology	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
70	CD	O
%	NN	O
and	CC	O
77	CD	O
%	NN	O
identity	NN	O
to	TO	O
the	DT	O
germ	JJ	O
line	NN	O
sequence	NN	O
of	IN	O
Human	NNP	O
VH1-8	NNP	O
and	CC	O
Vk1-18	NNP	O
respectively	RB	O
.	.	O
These	DT	O
germ	JJ	O
lines	NNS	O
were	VBD	O
picked	VBN	O
as	IN	O
the	DT	O
human	JJ	O
framework	NN	O
for	IN	O
the	DT	O
humanized	JJ	O
131-2G	JJ	O
mAb	NN	O
.	.	O
Epitope	NNP	O
mapping	NN	O
of	IN	O
mAb	$	O
1312G	CD	O
.	.	O
Western	JJ	O
Blot	NNP	O
analysis	NN	O
using	VBG	O
RSV	NNP	O
lysate	NN	O
and	CC	O
purified	VBD	O
Ga	NNP	O
protein	NN	O
suggested	VBD	O
that	IN	O
131-2G	JJ	O
recognizes	VBZ	O
a	DT	O
linear	JJ	O
epitope	NN	O
.	.	O
The	DT	O
binding	VBG	O
domain	NN	O
of	IN	O
131-2G	JJ	O
was	VBD	O
mapped	VBN	O
using	VBG	O
a	DT	O
set	NN	O
of	IN	O
overlapping	VBG	O
peptides	NNS	O
derived	VBN	O
from	IN	O
the	DT	O
RSV-GA2	NNP	O
protein	NN	O
sequence	NN	O
.	.	O
FIG	NNP	O
.	.	O
2A	CD	O
diagrams	VBZ	O
the	DT	O
G	NNP	O
protein	NN	O
sequence	NN	O
,	,	O
including	VBG	O
location	NN	O
of	IN	O
the	DT	O
conserved	JJ	O
CX3C	NNP	O
motif	NN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
obtain	VB	O
a	DT	O
fine	JJ	O
epitope	NN	O
mapping	NN	O
,	,	O
a	DT	O
scan	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
family	NN	O
of	IN	O
12-mer	JJ	O
Ga	NNP	O
derived	VBD	O
peptides	NNS	O
,	,	O
each	DT	O
shifted	VBN	O
by	IN	O
one	CD	O
residue	NN	O
.	.	O
An	DT	O
array	NN	O
of	IN	O
such	JJ	O
peptides	NNS	O
was	VBD	O
probed	VBN	O
with	IN	O
131-2G	JJ	O
mAb	NN	O
,	,	O
at	IN	O
1	CD	O
μg/ml	NN	O
.	.	O
Binding	NNP	O
of	IN	O
131-2G	NNP	O
was	VBD	O
detected	VBN	O
by	IN	O
goat	NN	O
anti	NN	O
mouse	IN	O
peroxidase-labeled	JJ	O
antibody	NN	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
super	JJ	O
signal	NN	O
chemiluminescence	NN	O
detection	NN	O
system	NN	O
(	(	O
Pierce	NNP	O
,	,	O
Rockford	NNP	O
Ill.	NNP	O
,	,	O
USA	NNP	O
)	)	O
.	.	O
As	IN	O
summarized	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
3	CD	O
,	,	O
the	DT	O
131-2G	JJ	O
antibody	NN	O
reacts	VBZ	O
with	IN	O
8	CD	O
consecutive	JJ	O
peptides	NNS	O
spanning	VBG	O
the	DT	O
RSV-Ga	JJ	O
protein	NN	O
from	IN	O
residue	JJ	O
157	CD	O
to	TO	O
176	CD	O
.	.	O
The	DT	O
epitope	NN	O
recognized	VBN	O
by	IN	O
131-2G	JJ	O
is	VBZ	O
within	IN	O
the	DT	O
peptide	NN	O
sequences	NNS	O
(	(	O
157	CD	O
)	)	O
SKPNNDFHFEVF	NNP	O
(	(	O
169	CD	O
)	)	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
and	CC	O
(	(	O
169	CD	O
)	)	O
HFEVFNFVPCSI	NNP	O
(	(	O
176	CD	O
)	)	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
common	JJ	O
sequence	NN	O
from	IN	O
the	DT	O
8	CD	O
peptides	NNS	O
,	,	O
the	DT	O
131-2G	JJ	O
binding	NN	O
domain	NN	O
was	VBD	O
mapped	VBN	O
to	TO	O
residues	VB	O
164-168	JJ	O
.	.	O
Three	CD	O
methods	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
characterize	VB	O
the	DT	O
affinity	NN	O
of	IN	O
131-2G	JJ	O
and	CC	O
analogous	JJ	O
human	JJ	O
mAbs	NN	O
.	.	O
First	RB	O
,	,	O
binding	VBG	O
signal	NN	O
was	VBD	O
measured	VBN	O
for	IN	O
a	DT	O
fixed	JJ	O
amount	NN	O
of	IN	O
antibody	NN	O
probed	VBN	O
against	IN	O
serial	JJ	O
dilutions	NNS	O
of	IN	O
antigen	NN	O
in	IN	O
an	DT	O
ELISA	NNP	O
format	NN	O
.	.	O
The	DT	O
midpoint	NN	O
of	IN	O
this	DT	O
titration	NN	O
curve	NN	O
is	VBZ	O
an	DT	O
approximation	NN	O
of	IN	O
the	DT	O
affinity	NN	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
131-2G	JJ	O
,	,	O
that	IN	O
midpoint	NN	O
is	VBZ	O
4	CD	O
nM	NN	O
.	.	O
Second	JJ	O
,	,	O
the	DT	O
affinity	NN	O
of	IN	O
131-2G	JJ	O
was	VBD	O
measured	VBN	O
by	IN	O
Biacore	NNP	O
analysis	NN	O
at	IN	O
a	DT	O
commercial	JJ	O
analytical	JJ	O
laboratory	NN	O
;	:	O
based	VBN	O
on	IN	O
the	DT	O
ratio	NN	O
of	IN	O
on-rate	JJ	O
to	TO	O
off-rate	JJ	O
,	,	O
the	DT	O
affinity	NN	O
was	VBD	O
calculated	VBN	O
as	IN	O
7	CD	O
nM	NN	O
.	.	O
Third	NNP	O
,	,	O
dilution	NN	O
of	IN	O
the	DT	O
Ga	NNP	O
protein	NN	O
on	IN	O
CellSpot™	NNP	O
beads	NNS	O
with	IN	O
serum	NN	O
albumin	NN	O
reduces	VBZ	O
the	DT	O
opportunity	NN	O
for	IN	O
multiple	JJ	O
copies	NNS	O
of	IN	O
the	DT	O
protein	NN	O
to	TO	O
interact	VB	O
with	IN	O
the	DT	O
antibody	NN	O
footprint	NN	O
.	.	O
The	DT	O
resulting	VBG	O
suppression	NN	O
of	IN	O
multi-dentate	JJ	O
avidity	NN	O
effects	NNS	O
from	IN	O
the	DT	O
raw	JJ	O
signal	NN	O
allows	NNS	O
rank	VBP	O
ordering	VBG	O
of	IN	O
a	DT	O
set	NN	O
of	IN	O
clones	NNS	O
for	IN	O
affinity	NN	O
,	,	O
relative	JJ	O
to	TO	O
a	DT	O
known	VBN	O
standard	NN	O
.	.	O
This	DT	O
measure	NN	O
of	IN	O
affinity	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
compare	VB	O
the	DT	O
human	JJ	O
antibodies	NNS	O
to	TO	O
131-2G	JJ	O
and	CC	O
efficiently	RB	O
select	VB	O
for	IN	O
high	JJ	O
affinity	NN	O
clones	NNS	O
.	.	O
All	DT	O
of	IN	O
these	DT	O
methods	NNS	O
are	VBP	O
improved	VBN	O
by	IN	O
availability	NN	O
of	IN	O
a	DT	O
consistent	JJ	O
source	NN	O
of	IN	O
G	NNP	O
protein	NN	O
antigen	NN	O
.	.	O
In	IN	O
our	PRP$	O
early	JJ	O
studies	NNS	O
,	,	O
antigen	NN	O
was	VBD	O
extracted	VBN	O
from	IN	O
virus	NN	O
infected	VBN	O
cells	NNS	O
.	.	O
Due	JJ	O
to	TO	O
variability	NN	O
in	IN	O
the	DT	O
quality	NN	O
of	IN	O
antigen	NN	O
prepared	VBN	O
this	DT	O
way	NN	O
,	,	O
we	PRP	O
developed	VBD	O
a	DT	O
recombinant	JJ	O
expression	NN	O
system	NN	O
for	IN	O
producing	VBG	O
the	DT	O
G	NNP	O
protein	NN	O
,	,	O
which	WDT	O
proved	VBD	O
to	TO	O
be	VB	O
more	RBR	O
reliable	JJ	O
.	.	O
Example	RB	O
2	CD	O
Isolation	NNP	O
of	IN	O
Human	NNP	O
B	NNP	O
Cells	NNP	O
Secreting	NNP	O
Antibody	NNP	O
to	TO	O
RSV-Ga/Gb	NNP	O
Peripheral	NNP	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
from	IN	O
40	CD	O
adults	NNS	O
with	IN	O
confirmed	JJ	O
RSV	NNP	O
infection	NN	O
were	VBD	O
surveyed	VBN	O
for	IN	O
human	JJ	O
B	NNP	O
cells	NNS	O
producing	VBG	O
anti-viral	JJ	O
antibodies	NNS	O
.	.	O
Subjects	NNS	O
with	IN	O
the	DT	O
desired	JJ	O
antibodies	NNS	O
against	IN	O
RSV	NNP	O
attachment	JJ	O
G	NNP	O
protein	NN	O
were	VBD	O
used	VBN	O
for	IN	O
cloning	VBG	O
of	IN	O
anti	JJ	O
RSV-G	NNP	O
specific	JJ	O
mAbs	NN	O
.	.	O
The	DT	O
result	NN	O
of	IN	O
the	DT	O
survey	NN	O
was	VBD	O
that	IN	O
˜10	NNP	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
had	VBD	O
a	DT	O
frequency	NN	O
of	IN	O
the	DT	O
desired	JJ	O
cells	NNS	O
greater	JJR	O
than	IN	O
1	CD	O
in	IN	O
100,000	CD	O
.	.	O
Even	RB	O
those	DT	O
with	IN	O
a	DT	O
lower	JJR	O
frequency	NN	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
of	IN	O
interest	NN	O
and	CC	O
in	IN	O
fact	NN	O
the	DT	O
highest	JJS	O
affinity	NN	O
antibody	NN	O
identified	VBD	O
came	VBD	O
from	IN	O
a	DT	O
donor	NN	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
frequency	NN	O
of	IN	O
the	DT	O
desired	VBN	O
B	NNP	O
cell	NN	O
type	NN	O
,	,	O
˜1	NNP	O
ppm	NN	O
.	.	O
To	TO	O
accomplish	VB	O
the	DT	O
survey	NN	O
and	CC	O
recovery	NN	O
of	IN	O
rare	JJ	O
favorable	JJ	O
cells	NNS	O
,	,	O
we	PRP	O
used	VBD	O
the	DT	O
previously	RB	O
described	VBN	O
CellSpot™	NNP	O
technology	NN	O
.	.	O
The	DT	O
CellSpot™	NNP	O
assay	VBP	O
method	NN	O
effectively	RB	O
shrinks	VBZ	O
an	DT	O
ELISA	NNP	O
equivalent	NN	O
assay	VBP	O
down	IN	O
to	TO	O
a	DT	O
virtual	JJ	O
well	NN	O
of	IN	O
near	JJ	O
single	JJ	O
cell	NN	O
dimensions	NNS	O
by	IN	O
capturing	VBG	O
secreted	VBN	O
IgG	NNP	O
from	IN	O
a	DT	O
single	JJ	O
cell	NN	O
as	IN	O
a	DT	O
footprint	NN	O
in	IN	O
the	DT	O
vicinity	NN	O
of	IN	O
the	DT	O
cell	NN	O
.	.	O
As	IN	O
a	DT	O
result	NN	O
,	,	O
millions	NNS	O
of	IN	O
cells	NNS	O
can	MD	O
be	VB	O
readily	RB	O
analyzed	VBN	O
.	.	O
Further	RB	O
,	,	O
by	IN	O
use	NN	O
of	IN	O
microscopic	NN	O
multiplexing	VBG	O
reagents	NNS	O
(	(	O
combinatorially	RB	O
colored	VBN	O
fluorescent	JJ	O
latex	NN	O
microspheres	NNS	O
,	,	O
cf	JJ	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,642,062	CD	O
)	)	O
,	,	O
each	DT	O
clone	NN	O
's	POS	O
secreted	VBN	O
antibody	NN	O
footprint	NN	O
can	MD	O
be	VB	O
characterized	VBN	O
in	IN	O
detail	NN	O
for	IN	O
specificity	NN	O
and/or	NN	O
affinity	NN	O
using	VBG	O
multiple	JJ	O
biochemical	JJ	O
probes	NNS	O
.	.	O
The	DT	O
fidelity	NN	O
of	IN	O
the	DT	O
quantitative	JJ	O
assay	NN	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
enable	VB	O
rescue	NN	O
of	IN	O
extremely	RB	O
rare	JJ	O
favorable	JJ	O
cells	NNS	O
from	IN	O
the	DT	O
survey	NN	O
population	NN	O
,	,	O
with	IN	O
the	DT	O
cloned	JJ	O
expression	NN	O
cell	NN	O
showing	VBG	O
a	DT	O
phenotype	JJ	O
consistent	NN	O
with	IN	O
the	DT	O
original	JJ	O
identifying	NN	O
assay	NN	O
.	.	O
The	DT	O
screening	NN	O
criteria	NNS	O
were	VBD	O
:	:	O
binding	NN	O
to	TO	O
G	NNP	O
protein	NN	O
from	IN	O
both	DT	O
of	IN	O
the	DT	O
two	CD	O
major	JJ	O
strain	NN	O
families	NNS	O
,	,	O
denoted	VBN	O
Ga	NNP	O
and	CC	O
Gb	NNP	O
,	,	O
and	CC	O
not	RB	O
binding	VBG	O
to	TO	O
the	DT	O
F	NNP	O
protein	NN	O
(	(	O
the	DT	O
other	JJ	O
major	JJ	O
viral	JJ	O
coat	NN	O
protein	NN	O
)	)	O
.	.	O
Affinity	NNP	O
rank	VBD	O
ordering	VBG	O
of	IN	O
clones	NNS	O
can	MD	O
also	RB	O
be	VB	O
accomplished	VBN	O
by	IN	O
diluting	VBG	O
the	DT	O
antigen	NN	O
on	IN	O
the	DT	O
bead	NN	O
with	IN	O
serum	JJ	O
albumin	NN	O
.	.	O
This	DT	O
reduces	VBZ	O
the	DT	O
chances	NNS	O
for	IN	O
multi-dentate	JJ	O
binding	NN	O
to	TO	O
the	DT	O
secreted	VBN	O
IgG	NNP	O
footprint	NN	O
(	(	O
an	DT	O
“	NN	O
avidity	NN	O
”	NNP	O
effect	NN	O
)	)	O
,	,	O
thus	RB	O
selecting	VBG	O
for	IN	O
higher	JJR	O
intrinsic	JJ	O
affinity	NN	O
.	.	O
G	NNP	O
protein	NN	O
was	VBD	O
purified	VBN	O
from	IN	O
Vero	NNP	O
cells	NNS	O
infected	VBN	O
with	IN	O
one	CD	O
or	CC	O
the	DT	O
other	JJ	O
of	IN	O
the	DT	O
two	CD	O
RSV	NNP	O
strains	NNS	O
.	.	O
Applied	VBN	O
to	TO	O
human	JJ	O
B	NNP	O
cells	NNS	O
,	,	O
the	DT	O
method	NN	O
begins	VBZ	O
by	IN	O
depleting	VBG	O
non-B	JJ	O
cells	NNS	O
from	IN	O
PBMCs	NNP	O
using	VBG	O
standard	JJ	O
magnetic	JJ	O
separation	NN	O
methods	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
resuspended	VBN	O
in	IN	O
IMDM/20	NNP	O
%	NN	O
HI-FCS	NNP	O
at	IN	O
1e6/ml	CD	O
;	:	O
EBV	NNP	O
(	(	O
direct	JJ	O
pelleted	VBN	O
from	IN	O
the	DT	O
supernatant	NN	O
of	IN	O
infected	JJ	O
B95-8	NNP	O
cells	NNS	O
)	)	O
was	VBD	O
added	VBN	O
at	IN	O
1:100	CD	O
dilution	NN	O
,	,	O
and	CC	O
the	DT	O
cells	NNS	O
incubated	VBD	O
2	CD	O
hr	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
Excess	NNP	O
virus	NN	O
was	VBD	O
washed	VBN	O
away	RB	O
,	,	O
and	CC	O
cells	NNS	O
either	CC	O
:	:	O
cultured	VBN	O
at	IN	O
2e6/ml	CD	O
in	IN	O
IMDM	NNP	O
,	,	O
20	CD	O
%	NN	O
HI-FCS	NNP	O
,	,	O
20	CD	O
%	NN	O
Giant	NNP	O
cell	NN	O
tumor	NN	O
conditioned	VBD	O
medium	NN	O
,	,	O
2	CD	O
μg/ml	NN	O
CpG	NNP	O
(	(	O
ODN2006	NNP	O
)	)	O
,	,	O
and	CC	O
10	CD	O
ng/ml	JJ	O
IL-10	NNP	O
for	IN	O
surveying	VBG	O
only	RB	O
,	,	O
or	CC	O
further	RB	O
selected	VBN	O
for	IN	O
surface	NN	O
IgG	NNP	O
using	VBG	O
magnetic	JJ	O
positive	JJ	O
selection	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
cultured	VBN	O
at	IN	O
200-300	JJ	O
cells/well	NN	O
on	IN	O
irradiated	JJ	O
human	JJ	O
lung	NN	O
cells	NNS	O
(	(	O
MRC-5	NNP	O
,	,	O
5,000	CD	O
cells/well	NN	O
)	)	O
in	IN	O
IMDM	NNP	O
,	,	O
20	CD	O
%	NN	O
HI-FCS	NNP	O
,	,	O
20	CD	O
%	NN	O
Giant	NNP	O
cell	NN	O
tumor	NN	O
conditioned	VBD	O
medium	NN	O
,	,	O
2	CD	O
μg/ml	NN	O
CpG	NNP	O
(	(	O
ODN2006	NNP	O
)	)	O
,	,	O
and	CC	O
10	CD	O
ng/ml	JJ	O
IL-10	NNP	O
.	.	O
Medium	NN	O
was	VBD	O
supplemented	VBN	O
every	DT	O
2-3	JJ	O
days	NNS	O
.	.	O
One	CD	O
half	NN	O
of	IN	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
wells	NNS	O
were	VBD	O
assayed	VBN	O
in	IN	O
CellSpot™	NNP	O
at	IN	O
day	NN	O
6	CD	O
.	.	O
The	DT	O
remaining	VBG	O
cells	NNS	O
in	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
wells	NNS	O
positive	JJ	O
by	IN	O
the	DT	O
survey	NN	O
assay	VBP	O
were	VBD	O
then	RB	O
diluted	VBN	O
to	TO	O
10	CD	O
,	,	O
5	CD	O
,	,	O
1	CD	O
,	,	O
and	CC	O
0.5	CD	O
cells/well	NN	O
with	IN	O
the	DT	O
same	JJ	O
feeder	NN	O
cells	NNS	O
and	CC	O
culture	NN	O
conditions	NNS	O
.	.	O
After	IN	O
4-5	JJ	O
days	NNS	O
these	DT	O
limiting	VBG	O
dilution	NN	O
plates	NNS	O
were	VBD	O
again	RB	O
assayed	VBN	O
by	IN	O
ELISA	NNP	O
or	CC	O
CellSpot™	NNP	O
.	.	O
Contents	NNS	O
of	IN	O
positive	JJ	O
wells	NNS	O
at	IN	O
limiting	VBG	O
dilution	NN	O
were	VBD	O
then	RB	O
processed	VBN	O
using	VBG	O
Reverse	NNP	O
Transcriptase-PCR	NNP	O
to	TO	O
recover	VB	O
the	DT	O
encoding	NN	O
polynucleotide	NN	O
for	IN	O
the	DT	O
antibody	NN	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
.	.	O
Total	JJ	O
time	NN	O
from	IN	O
thawing	VBG	O
PBMCs	NNP	O
to	TO	O
recovery	NN	O
of	IN	O
the	DT	O
encoding	VBG	O
mRNA	JJ	O
sequence	NN	O
via	IN	O
RT-PCR	NNP	O
was	VBD	O
10-12	JJ	O
days	NNS	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
shows	NNS	O
illustrative	JJ	O
data	NNS	O
from	IN	O
this	DT	O
experiment	NN	O
.	.	O
Examples	NNS	O
of	IN	O
CellSpot™	NNP	O
profiling	NN	O
of	IN	O
favorable	JJ	O
and	CC	O
unfavorable	JJ	O
donor	NN	O
blood	NN	O
samples	NNS	O
is	VBZ	O
illustrated	VBN	O
in	IN	O
panels	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O
The	DT	O
profile	NN	O
of	IN	O
a	DT	O
favorable	JJ	O
clone	NN	O
at	IN	O
initial	JJ	O
detection	NN	O
is	VBZ	O
shown	VBN	O
in	IN	O
panel	NN	O
C	NNP	O
,	,	O
along	IN	O
with	IN	O
replicate	NN	O
profiles	NNS	O
in	IN	O
panel	NN	O
D	NNP	O
of	IN	O
antibody	NN	O
secreted	VBN	O
from	IN	O
progeny	NN	O
of	IN	O
a	DT	O
HEK293	NNP	O
cell	NN	O
transformed	VBD	O
with	IN	O
cDNA	NN	O
cloned	VBN	O
antibody	NN	O
derived	VBN	O
from	IN	O
that	DT	O
cell	NN	O
.	.	O
The	DT	O
profiles	NNS	O
are	VBP	O
identical	JJ	O
within	IN	O
the	DT	O
precision	NN	O
of	IN	O
the	DT	O
assay	NN	O
,	,	O
indicating	VBG	O
successful	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
favorable	JJ	O
clone	NN	O
.	.	O
As	IN	O
was	VBD	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
the	DT	O
majority	NN	O
of	IN	O
anti-RSV	JJ	O
antibodies	NNS	O
are	VBP	O
directed	VBN	O
to	TO	O
the	DT	O
F	NNP	O
protein	NN	O
or	CC	O
to	TO	O
an	DT	O
antigenic	JJ	O
determinant	NN	O
shared	VBN	O
by	IN	O
F	NNP	O
and	CC	O
G	NNP	O
(	(	O
most	JJS	O
likely	RB	O
carbohydrate	NN	O
since	IN	O
the	DT	O
two	CD	O
proteins	NNS	O
have	VBP	O
no	DT	O
sequence	NN	O
homology	NN	O
)	)	O
.	.	O
Of	IN	O
the	DT	O
G	NNP	O
specific	JJ	O
antibodies	NNS	O
,	,	O
most	JJS	O
bind	IN	O
only	JJ	O
Ga	NNP	O
or	CC	O
only	RB	O
Gb	NNP	O
,	,	O
consistent	NN	O
with	IN	O
the	DT	O
known	VBN	O
high	JJ	O
sequence	NN	O
variability	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
.	.	O
Overall	JJ	O
,	,	O
˜20	JJ	O
million	CD	O
individual	JJ	O
B	NNP	O
cells	NNS	O
were	VBD	O
surveyed	VBN	O
.	.	O
The	DT	O
12	CD	O
most	JJS	O
promising	JJ	O
antibodies	NNS	O
were	VBD	O
recovered	VBN	O
by	IN	O
RT-PCR	NNP	O
.	.	O
Overall	JJ	O
,	,	O
then	RB	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
favorable	JJ	O
clones	NNS	O
is	VBZ	O
below	IN	O
1	CD	O
in	IN	O
1	CD	O
million	CD	O
,	,	O
and	CC	O
over	IN	O
50	CD	O
million	CD	O
ELISA	NNP	O
equivalent	JJ	O
assays	NNS	O
were	VBD	O
needed	VBN	O
to	TO	O
find	VB	O
those	DT	O
rare	JJ	O
clones	NNS	O
.	.	O
The	DT	O
CellSpot™	NNP	O
technology	NN	O
thus	RB	O
enabled	VBD	O
a	DT	O
more	RBR	O
comprehensive	JJ	O
survey	NN	O
of	IN	O
clones	NNS	O
than	IN	O
would	MD	O
otherwise	RB	O
be	VB	O
practical	JJ	O
.	.	O
The	DT	O
quality	NN	O
of	IN	O
the	DT	O
resulting	VBG	O
clones	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
those	DT	O
found	VBN	O
by	IN	O
more	JJR	O
limiting	NN	O
screening	NN	O
,	,	O
and	CC	O
the	DT	O
consensus	NN	O
features	NNS	O
of	IN	O
that	DT	O
high	JJ	O
quality	NN	O
set	VBN	O
reveal	NN	O
unanticipated	JJ	O
features	NNS	O
of	IN	O
the	DT	O
desired	JJ	O
antibodies	NNS	O
.	.	O
Example	RB	O
3	CD	O
Cloning	NNP	O
of	IN	O
Human	NNP	O
Antibodies	NNPS	O
to	TO	O
RSV-Ga/Gb	NNP	O
Amplification	NNP	O
of	IN	O
rearranged	VBN	O
Ig	NNP	O
Heavy	NNP	O
and	CC	O
Ig	NNP	O
Light	NNP	O
genes	NNS	O
from	IN	O
positive	JJ	O
ELISA	NNP	O
wells	NNS	O
was	VBD	O
accomplished	VBN	O
using	VBG	O
semi-nested	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
.	.	O
For	IN	O
amplification	NN	O
of	IN	O
a	DT	O
priori	JJ	O
unknown	JJ	O
V-gene	NNP	O
rearrangements	NNS	O
,	,	O
a	DT	O
collection	NN	O
of	IN	O
family-specific	JJ	O
V-gene	NNP	O
primers	NNS	O
was	VBD	O
constructed	VBN	O
,	,	O
which	WDT	O
recognize	VBP	O
nearly	RB	O
all	DT	O
V-gene	JJ	O
segments	NNS	O
in	IN	O
the	DT	O
human	JJ	O
Ig	NNP	O
Locus	NNP	O
.	.	O
The	DT	O
5′	CD	O
primers	NNS	O
were	VBD	O
used	VBN	O
together	RB	O
with	IN	O
primer	NN	O
mixes	NNS	O
specific	JJ	O
for	IN	O
the	DT	O
Cγ	NNP	O
,	,	O
Cκ	NNP	O
and	CC	O
Cλ	NNP	O
gene	NN	O
segments	NNS	O
.	.	O
The	DT	O
clonality	NN	O
of	IN	O
the	DT	O
limiting	JJ	O
dilution	NN	O
RSV-G	NNP	O
specific	NN	O
B	NNP	O
cells	NNS	O
was	VBD	O
unequivocally	RB	O
determined	VBN	O
by	IN	O
sequence	NN	O
comparison	NN	O
of	IN	O
V-gene	NNP	O
amplificates	NNS	O
from	IN	O
distinct	JJ	O
progeny	NN	O
cells	NNS	O
,	,	O
and	CC	O
the	DT	O
amplified	JJ	O
full	JJ	O
length	NN	O
V-gene	JJ	O
rearrangements	NNS	O
were	VBD	O
cloned	VBN	O
into	IN	O
IgG	NNP	O
expression	NN	O
vectors	NNS	O
.	.	O
This	DT	O
method	NN	O
was	VBD	O
also	RB	O
useful	JJ	O
to	TO	O
address	VB	O
additional	JJ	O
issues	NNS	O
,	,	O
such	JJ	O
as	IN	O
V-	NNP	O
,	,	O
D-	NNP	O
,	,	O
and	CC	O
J-gene	NNP	O
usage	NN	O
and	CC	O
the	DT	O
presence	NN	O
and	CC	O
pattern	NN	O
of	IN	O
somatic	JJ	O
mutations	NNS	O
.	.	O
Methods	NNS	O
.	.	O
Total	JJ	O
mRNA	NN	O
from	IN	O
the	DT	O
isolated	JJ	O
human	NN	O
B	NNP	O
cells	NNS	O
was	VBD	O
extracted	VBN	O
using	VBG	O
a	DT	O
commercially	RB	O
available	JJ	O
RNA	NNP	O
purification	NN	O
kit	NN	O
(	(	O
RNeasy™	NNP	O
;	:	O
Qiagen	NNP	O
(	(	O
Germany	NNP	O
)	)	O
)	)	O
.	.	O
Reverse	JJ	O
transcription-PCR	NN	O
was	VBD	O
done	VBN	O
by	IN	O
using	VBG	O
total	JJ	O
RNA	NNP	O
preparations	NNS	O
and	CC	O
oligonucleotides	NNS	O
as	IN	O
primers	NNS	O
.	.	O
Three	CD	O
PCR	NNP	O
reactions	NNS	O
were	VBD	O
run	VBN	O
for	IN	O
each	DT	O
sample	NN	O
:	:	O
one	CD	O
for	IN	O
light	NN	O
chain	NN	O
kappa	NN	O
(	(	O
κ	NNP	O
)	)	O
one	CD	O
for	IN	O
light	NN	O
chain	NN	O
lambda	NN	O
(	(	O
λ	NNP	O
)	)	O
,	,	O
and	CC	O
one	CD	O
for	IN	O
gamma	NN	O
heavy	NN	O
chain	NN	O
(	(	O
γ	NNP	O
)	)	O
.	.	O
The	DT	O
QIAGEN®	NNP	O
OneStep	NNP	O
RT-PCR	NNP	O
kit	NN	O
was	VBD	O
used	VBN	O
for	IN	O
amplification	NN	O
,	,	O
(	(	O
Qiagen	NNP	O
Catalog	NNP	O
No	NNP	O
.	.	O
210212	CD	O
)	)	O
.	.	O
In	IN	O
the	DT	O
coupled	JJ	O
RT-PCR	JJ	O
reactions	NNS	O
,	,	O
cDNA	NN	O
is	VBZ	O
synthesized	VBN	O
with	IN	O
unique	JJ	O
blend	NN	O
of	IN	O
RT	NNP	O
enzymes	NNS	O
(	(	O
Omniscript™	NNP	O
and	CC	O
Sensiscript™	NNP	O
)	)	O
using	VBG	O
antisense	JJ	O
sequence	NN	O
specific	JJ	O
primer	NN	O
corresponded	VBD	O
to	TO	O
C-κ	NNP	O
,	,	O
C-λ	NNP	O
or	CC	O
to	TO	O
a	DT	O
consensus	NN	O
of	IN	O
the	DT	O
CH1	NNP	O
regions	NNS	O
of	IN	O
Cγ	NNP	O
genes	NNS	O
,	,	O
RT	NNP	O
is	VBZ	O
preformed	VBN	O
at	IN	O
50°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
hour	NN	O
followed	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
by	IN	O
HotStarTaq	NNP	O
DNA	NNP	O
Polymerase	NNP	O
for	IN	O
high	JJ	O
specificity	NN	O
and	CC	O
sensitivity	NN	O
.	.	O
Each	DT	O
PCR	NNP	O
reaction	NN	O
used	VBD	O
a	DT	O
mixture	NN	O
of	IN	O
5′	CD	O
sense	NN	O
primers	NNS	O
.	.	O
Primer	NN	O
sequences	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
leader	NN	O
sequences	NNS	O
of	IN	O
VH	NNP	O
,	,	O
VK	NNP	O
and	CC	O
VL	NNP	O
.	.	O
PCR	JJ	O
reactions	NNS	O
were	VBD	O
run	VBN	O
at	IN	O
95°	CD	O
C.	NNP	O
for	IN	O
15	CD	O
minutes	NNS	O
,	,	O
initial	JJ	O
hot	JJ	O
start	NN	O
followed	VBN	O
by	IN	O
20	CD	O
cycles	NNS	O
of	IN	O
95°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
seconds	NNS	O
(	(	O
denaturation	NN	O
)	)	O
,	,	O
60°	CD	O
C.	NNP	O
for	IN	O
45	CD	O
seconds	NNS	O
(	(	O
annealing	VBG	O
)	)	O
and	CC	O
72°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
minute	NN	O
(	(	O
elongation	NN	O
)	)	O
.	.	O
Nested	VBN	O
PCR	NNP	O
for	IN	O
detection	NN	O
and	CC	O
cloning	NN	O
of	IN	O
the	DT	O
variable	JJ	O
Ig	NNP	O
fragments	NNS	O
into	IN	O
expression	NN	O
vectors	NNS	O
.	.	O
In	IN	O
the	DT	O
second	JJ	O
round	NN	O
,	,	O
an	DT	O
aliquot	NN	O
of	IN	O
5	CD	O
μl	NN	O
of	IN	O
the	DT	O
first	JJ	O
amplification	NN	O
reaction	NN	O
was	VBD	O
applied	VBN	O
.	.	O
The	DT	O
primers	NNS	O
used	VBD	O
carry	VBP	O
the	DT	O
5′BglII	CD	O
and	CC	O
3′	CD	O
XbaI	NNP	O
restriction	NN	O
sites	NNS	O
.	.	O
Thirty	NNP	O
PCR	NNP	O
cycles	NNS	O
were	VBD	O
performed	VBN	O
.	.	O
Identical	JJ	O
conditions	NNS	O
were	VBD	O
used	VBN	O
for	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
rounds	NNS	O
of	IN	O
amplification	NN	O
.	.	O
Five	CD	O
microliters	NNS	O
of	IN	O
each	DT	O
reaction	NN	O
were	VBD	O
loaded	VBN	O
and	CC	O
separated	VBN	O
on	IN	O
a	DT	O
1	CD	O
%	NN	O
agarose	JJ	O
gel	NN	O
and	CC	O
then	RB	O
stained	VBD	O
with	IN	O
ethidium	NN	O
bromide	NN	O
.	.	O
The	DT	O
V-C	NNP	O
PCR	NNP	O
product	NN	O
is	VBZ	O
predicted	VBN	O
to	TO	O
amplify	VB	O
rearranged	JJ	O
fragments	NNS	O
of	IN	O
VH	NNP	O
and	CC	O
VL	NNP	O
,	,	O
500	CD	O
and	CC	O
450	CD	O
bp	NN	O
respectively	RB	O
.	.	O
PCR	NNP	O
bands	VBZ	O
with	IN	O
a	DT	O
molecular	JJ	O
size	NN	O
of	IN	O
approximately	RB	O
500	CD	O
bp	NNS	O
indicated	VBD	O
a	DT	O
positive	JJ	O
result	NN	O
.	.	O
PCR	NN	O
products	NNS	O
were	VBD	O
purified	VBN	O
(	(	O
Qiagen	NNP	O
gel	VBZ	O
purification	NN	O
kit	NN	O
catalog	NN	O
number	NN	O
28704	CD	O
)	)	O
and	CC	O
the	DT	O
extracted	VBN	O
PCR	NNP	O
products	NNS	O
were	VBD	O
directly	RB	O
sequenced	VBN	O
using	VBG	O
specific	JJ	O
constant	JJ	O
region	NN	O
primers	NNS	O
.	.	O
The	DT	O
sequences	NNS	O
of	IN	O
the	DT	O
cloned	JJ	O
fragments	NNS	O
were	VBD	O
confirmed	VBN	O
by	IN	O
sequencing	VBG	O
plasmids	NNS	O
prepared	VBD	O
for	IN	O
recombinant	JJ	O
production	NN	O
.	.	O
FIG	NNP	O
.	.	O
5A	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:28-41	NNP	O
)	)	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
heavy	JJ	O
chains	NNS	O
of	IN	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
isolated	VBD	O
from	IN	O
human	JJ	O
subjects	NNS	O
as	RB	O
well	RB	O
as	IN	O
of	IN	O
humanized	JJ	O
131-2G	JJ	O
,	,	O
including	VBG	O
variable	JJ	O
region	NN	O
,	,	O
the	DT	O
D	NNP	O
and	CC	O
J	NNP	O
joining	NN	O
regions	NNS	O
,	,	O
the	DT	O
framework	NN	O
(	(	O
FR	NNP	O
)	)	O
and	CC	O
complementarity	NN	O
determining	NN	O
(	(	O
CDR	NNP	O
)	)	O
regions	NNS	O
.	.	O
All	DT	O
of	IN	O
the	DT	O
listed	VBN	O
antibodies	NNS	O
are	VBP	O
immunoreactive	JJ	O
with	IN	O
the	DT	O
G	NNP	O
protein	NN	O
from	IN	O
both	CC	O
the	DT	O
A	NNP	O
and	CC	O
B	NNP	O
strains	NNS	O
except	IN	O
for	IN	O
antibody	NN	O
3F9	CD	O
,	,	O
which	WDT	O
is	VBZ	O
immunoreactive	JJ	O
only	RB	O
with	IN	O
G	NNP	O
protein	NN	O
from	IN	O
strain	NN	O
A	NNP	O
.	.	O
FIG	NNP	O
.	.	O
5B	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOS:42-55	NNP	O
)	)	O
shows	VBZ	O
similar	JJ	O
sequence	NN	O
information	NN	O
for	IN	O
the	DT	O
light	JJ	O
chains	NNS	O
of	IN	O
these	DT	O
antibodies	NNS	O
.	.	O
Dashes	NNS	O
in	IN	O
the	DT	O
sequence	NN	O
listings	NNS	O
represent	VBP	O
alignment	JJ	O
corrections	NNS	O
in	IN	O
the	DT	O
gene	NN	O
sequences	NNS	O
of	IN	O
different	JJ	O
lengths	NNS	O
.	.	O
The	DT	O
PCR	NNP	O
fragments	NNS	O
described	VBN	O
above	IN	O
were	VBD	O
digested	VBN	O
and	CC	O
cloned	VBN	O
into	IN	O
individual	JJ	O
expression	NN	O
vectors	NNS	O
carrying	VBG	O
the	DT	O
constant	JJ	O
region	NN	O
of	IN	O
human	JJ	O
gamma	NN	O
1	CD	O
,	,	O
or	CC	O
of	IN	O
human	JJ	O
kappa	NN	O
or	CC	O
lambda	NN	O
,	,	O
for	IN	O
in	IN	O
vitro	NN	O
antibody	NN	O
production	NN	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
.	.	O
The	DT	O
expression	NN	O
vectors	NNS	O
coding	VBG	O
for	IN	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
were	VBD	O
co-transfected	JJ	O
into	IN	O
the	DT	O
293	CD	O
(	(	O
human	JJ	O
kidney	NN	O
)	)	O
cell	NN	O
line	NN	O
(	(	O
Invitrogen	NNP	O
)	)	O
.	.	O
The	DT	O
expression	NN	O
plasmids	NNS	O
were	VBD	O
introduced	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
cationic	JJ	O
lipid-based	JJ	O
transfection	NN	O
reagent	NN	O
(	(	O
293Fectin™	CD	O
;	:	O
Invitrogen	NNP	O
)	)	O
.	.	O
For	IN	O
each	DT	O
transfection	NN	O
reaction	NN	O
,	,	O
20	CD	O
μg	NN	O
of	IN	O
purified	JJ	O
plasmids	NNS	O
and	CC	O
40	CD	O
μL	NN	O
of	IN	O
the	DT	O
293Fectin™	CD	O
were	VBD	O
mixed	JJ	O
with	IN	O
1	CD	O
mL	NNS	O
of	IN	O
Opti-MEM®	NNP	O
(	(	O
Invitrogen	NNP	O
)	)	O
and	CC	O
incubated	VBN	O
for	IN	O
5	CD	O
min	NN	O
at	IN	O
room	NN	O
temperature	NN	O
before	IN	O
being	VBG	O
combined	VBN	O
and	CC	O
allowed	VBN	O
to	TO	O
form	VB	O
complexes	NNS	O
for	IN	O
20	CD	O
min	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
The	DT	O
DNA-293fectin	NNP	O
complexes	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
3×106	CD	O
cells	NNS	O
seeded	VBN	O
in	IN	O
90	CD	O
mm	NNS	O
petri	JJ	O
plates	NNS	O
and	CC	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
,	,	O
8	CD	O
%	NN	O
CO2	NNP	O
.	.	O
In	IN	O
the	DT	O
final	JJ	O
procedure	NN	O
,	,	O
the	DT	O
supernatant	NN	O
was	VBD	O
harvested	VBN	O
72	CD	O
hrs	JJ	O
post-transfection	NN	O
by	IN	O
centrifugation	NN	O
(	(	O
3,000	CD	O
g	NN	O
,	,	O
15	CD	O
min	NN	O
at	IN	O
4°	CD	O
C.	NNP	O
)	)	O
,	,	O
to	TO	O
recover	VB	O
the	DT	O
secreted	JJ	O
antibodies	NNS	O
.	.	O
Example	RB	O
4	CD	O
Epitope	NNP	O
Mapping	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
Antibodies	NNPS	O
and	CC	O
Affinity	NNP	O
Determination	NNP	O
Using	VBG	O
the	DT	O
technique	NN	O
described	VBN	O
in	IN	O
Example	NNP	O
1	CD	O
with	IN	O
respect	NN	O
to	TO	O
epitope	VB	O
mapping	NN	O
of	IN	O
the	DT	O
prior	JJ	O
art	NN	O
antibody	NN	O
131-2G	JJ	O
,	,	O
the	DT	O
epitopes	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
were	VBD	O
determined	VBN	O
.	.	O
The	DT	O
affinity	NN	O
of	IN	O
the	DT	O
invention	NN	O
antibodies	NNS	O
was	VBD	O
determined	VBN	O
using	VBG	O
the	DT	O
methods	NNS	O
described	VBN	O
in	IN	O
Example	NNP	O
1	CD	O
with	IN	O
respect	NN	O
to	TO	O
mAb	VB	O
131-2G	JJ	O
.	.	O
As	IN	O
noted	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
,	,	O
three	CD	O
of	IN	O
the	DT	O
antibodies	NNS	O
bind	VBP	O
a	DT	O
conformational	JJ	O
epitope—i.e.	NN	O
,	,	O
they	PRP	O
do	VBP	O
not	RB	O
map	VB	O
by	IN	O
binding	VBG	O
overlapping	VBG	O
peptides	NNS	O
.	.	O
Antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
which	WDT	O
map	NN	O
to	TO	O
specific	JJ	O
sequences	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
the	DT	O
table	NN	O
.	.	O
Also	RB	O
shown	VBN	O
are	VBP	O
the	DT	O
affinity	NN	O
constants	NNS	O
,	,	O
determined	VBD	O
using	VBG	O
standard	JJ	O
Biacore	NNP	O
assays	NNS	O
with	IN	O
respect	NN	O
to	TO	O
recombinant	VB	O
Ga	NNP	O
and	CC	O
Gb	NNP	O
proteins	NNS	O
expressed	VBD	O
as	IN	O
pM	NN	O
,	,	O
calculated	VBN	O
from	IN	O
the	DT	O
measured	VBN	O
on	IN	O
and	CC	O
off	IN	O
rates	NNS	O
.	.	O
The	DT	O
data	NNS	O
for	IN	O
two	CD	O
of	IN	O
these	DT	O
antibodies	NNS	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
Panels	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
show	VBP	O
binding	VBG	O
data	NNS	O
for	IN	O
3G12	CD	O
and	CC	O
panels	NNS	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
F	NNP	O
show	VBP	O
the	DT	O
data	NN	O
from	IN	O
3D3	CD	O
.	.	O
The	DT	O
top	JJ	O
row	NN	O
shows	VBZ	O
loading	NN	O
of	IN	O
the	DT	O
biosensor	NN	O
chip	NN	O
with	IN	O
antibody	NN	O
,	,	O
the	DT	O
middle	NN	O
row	NN	O
shows	VBZ	O
the	DT	O
signal	JJ	O
arising	NN	O
from	IN	O
flowing	VBG	O
Ga	NNP	O
protein	NN	O
across	IN	O
the	DT	O
chip	NN	O
followed	VBN	O
by	IN	O
washing	VBG	O
with	IN	O
buffer	NN	O
,	,	O
and	CC	O
the	DT	O
bottom	NN	O
row	NN	O
shows	VBZ	O
the	DT	O
same	JJ	O
thing	NN	O
for	IN	O
Gb	NNP	O
protein	NN	O
.	.	O
The	DT	O
increase	NN	O
in	IN	O
signal	JJ	O
allows	NNS	O
calculation	NN	O
of	IN	O
the	DT	O
on-rate	JJ	O
,	,	O
while	IN	O
the	DT	O
decrease	NN	O
during	IN	O
washing	VBG	O
allows	JJ	O
calculation	NN	O
of	IN	O
the	DT	O
off-rate	NN	O
.	.	O
The	DT	O
ratio	NN	O
of	IN	O
on	IN	O
to	TO	O
off	VB	O
rates	NNS	O
is	VBZ	O
the	DT	O
affinity	NN	O
constant	NN	O
,	,	O
Kd	NNP	O
.	.	O
Example	RB	O
5	CD	O
Comparison	NNP	O
of	IN	O
Binding	NNP	O
to	TO	O
G	NNP	O
Protein	NNP	O
with	IN	O
Binding	NNP	O
to	TO	O
Virions	NNP	O
FIG	NNP	O
.	.	O
7	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
an	DT	O
ELISA	NNP	O
assay	VBP	O
employing	VBG	O
live	JJ	O
virus	NN	O
and	CC	O
assessing	VBG	O
the	DT	O
binding	NN	O
using	VBG	O
a	DT	O
standard	JJ	O
horseradish	JJ	O
peroxidase	NN	O
assay	NN	O
.	.	O
Viral	JJ	O
preps	NNS	O
from	IN	O
various	JJ	O
sources	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
coat	VB	O
plates	NNS	O
at	IN	O
105	CD	O
PFU/well	NNP	O
or	CC	O
higher	JJR	O
concentration	NN	O
in	IN	O
carbonate	NN	O
buffer	NN	O
at	IN	O
pH	$	O
9.6	CD	O
overnight	VBN	O
at	IN	O
4°	CD	O
C.	NNP	O
Plates	NNPS	O
were	VBD	O
blocked	VBN	O
in	IN	O
5	CD	O
%	NN	O
mik	NN	O
with	IN	O
PBST	NNP	O
for	IN	O
an	DT	O
hour	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
Serial	JJ	O
dilutions	NNS	O
of	IN	O
antibodies	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
wells	NNS	O
in	IN	O
blocking	VBG	O
buffer	NN	O
for	IN	O
one	CD	O
hour	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
For	IN	O
detection	NN	O
,	,	O
1:2000	CD	O
dilution	NN	O
of	IN	O
goat	NN	O
anti-human	JJ	O
Fc	NNP	O
gamma—HRP	NN	O
(	(	O
Jackson	NNP	O
Immuno	NNP	O
.	.	O
)	)	O
was	VBD	O
added	VBN	O
in	IN	O
blocking	VBG	O
buffer	NN	O
for	IN	O
one	CD	O
hour	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
Plates	NNS	O
were	VBD	O
washed	VBN	O
extensively	RB	O
in	IN	O
PBST	NNP	O
.	.	O
Turnover	NN	O
of	IN	O
the	DT	O
substrate	NN	O
TMB	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
450	CD	O
nm	NNS	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
7	CD	O
,	,	O
3D3	CD	O
binds	NNS	O
well	RB	O
to	TO	O
the	DT	O
live	JJ	O
virus	NN	O
as	IN	O
do	VBP	O
a	DT	O
number	NN	O
of	IN	O
other	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
Synagis®	NNP	O
antibody	NN	O
,	,	O
which	WDT	O
has	VBZ	O
substantially	RB	O
weaker	JJR	O
affinity	NN	O
,	,	O
shows	VBZ	O
little	JJ	O
binding	VBG	O
to	TO	O
live	VB	O
virus	NN	O
even	RB	O
at	IN	O
104	CD	O
ng/ml	JJ	O
antibody	NN	O
.	.	O
FIG	NNP	O
.	.	O
8	CD	O
shows	VBZ	O
the	DT	O
correlation	NN	O
of	IN	O
the	DT	O
binding	NN	O
to	TO	O
recombinant	VB	O
protein	NN	O
as	IN	O
compared	VBN	O
to	TO	O
binding	VBG	O
to	TO	O
virus	VB	O
particles	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
9A	CD	O
and	CC	O
9B	CD	O
are	VBP	O
graphs	VBN	O
that	IN	O
demonstrate	NN	O
comparative	JJ	O
ability	NN	O
of	IN	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
bind	VB	O
to	TO	O
strains	NNS	O
A2	NNP	O
versus	NN	O
A5	NNP	O
,	,	O
using	VBG	O
the	DT	O
assay	NN	O
described	VBN	O
above	IN	O
.	.	O
FIG	NNP	O
.	.	O
9A	CD	O
shows	NNS	O
that	IN	O
3D3	CD	O
and	CC	O
3G12	CD	O
bind	NN	O
well	NN	O
to	TO	O
strain	VB	O
A2	NNP	O
as	IN	O
compared	VBN	O
to	TO	O
Synagis®	NNP	O
.	.	O
PAB	NNP	O
is	VBZ	O
a	DT	O
commercial	JJ	O
polyclonal	NN	O
goat	NN	O
antibody	NN	O
against	IN	O
all	DT	O
RSV	NNP	O
proteins	NNS	O
(	(	O
Chemicon	NNP	O
,	,	O
catalog	NN	O
#	#	O
AB1128	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
9B	CD	O
shows	NNS	O
that	IN	O
these	DT	O
antibodies	NNS	O
also	RB	O
bind	VBP	O
strain	JJ	O
A5	NNP	O
;	:	O
note	VBP	O
the	DT	O
units	NNS	O
on	IN	O
X-axis	NNS	O
are	VBP	O
different	JJ	O
than	IN	O
in	IN	O
FIG	NNP	O
.	.	O
9A	CD	O
.	.	O
Similar	JJ	O
experiments	NNS	O
show	VBP	O
that	IN	O
the	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
bind	NN	O
to	TO	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
clinical	JJ	O
isolates	NNS	O
.	.	O
Example	RB	O
6	CD	O
Neutralization	NNP	O
Assays	NNPS	O
The	DT	O
ability	NN	O
of	IN	O
selected	VBN	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
neutralize	VB	O
virus	NN	O
in	IN	O
vitro	NN	O
was	VBD	O
obtained	VBN	O
by	IN	O
a	DT	O
standard	JJ	O
plaque	NN	O
assay	NN	O
.	.	O
HEp2	NNP	O
cells	NNS	O
were	VBD	O
plated	VBN	O
in	IN	O
12-well	JJ	O
plates	NNS	O
at	IN	O
2×105	CD	O
cells/well	NN	O
.	.	O
The	DT	O
following	JJ	O
day	NN	O
,	,	O
serial	JJ	O
dilutions	NNS	O
of	IN	O
antibodies	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
media	NNS	O
.	.	O
Approximately	RB	O
200	CD	O
PFU/well	NNP	O
of	IN	O
RSV	NNP	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
antibodies	NNS	O
,	,	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
rabbit	NN	O
complement	NN	O
serum	NN	O
for	IN	O
one	CD	O
hour	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
The	DT	O
antibody-virus	JJ	O
mixture	NN	O
was	VBD	O
then	RB	O
added	VBN	O
to	TO	O
HEp2	NNP	O
cells	NNS	O
at	IN	O
200	CD	O
uL/well	NN	O
for	IN	O
2	CD	O
hr	NN	O
at	IN	O
room	NN	O
temperature	NN	O
to	TO	O
allow	VB	O
for	IN	O
infection	NN	O
.	.	O
Following	VBG	O
this	DT	O
infection	NN	O
period	NN	O
,	,	O
media	NNS	O
were	VBD	O
removed	VBN	O
and	CC	O
media	NNS	O
containing	VBG	O
1	CD	O
%	NN	O
methyl	NN	O
cellulose	NN	O
were	VBD	O
added	VBN	O
to	TO	O
all	DT	O
wells	NNS	O
.	.	O
Plates	NNS	O
were	VBD	O
incubated	VBN	O
at	IN	O
35°	CD	O
C.	NNP	O
for	IN	O
6	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
time	NN	O
,	,	O
cells	NNS	O
were	VBD	O
fixed	VBN	O
and	CC	O
stained	VBN	O
for	IN	O
plaque	JJ	O
number	NN	O
determination	NN	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
Methyl	NNP	O
cellulose	NN	O
is	VBZ	O
aspirated	VBN	O
from	IN	O
the	DT	O
cell	NN	O
layers	NNS	O
,	,	O
and	CC	O
cells	NNS	O
are	VBP	O
fixed	VBN	O
in	IN	O
100	CD	O
%	NN	O
methanol	NN	O
for	IN	O
30	CD	O
min	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
The	DT	O
plates	NNS	O
are	VBP	O
then	RB	O
washed	VBD	O
3×	CD	O
with	IN	O
5	CD	O
%	NN	O
milk	NN	O
in	IN	O
PBS	NNP	O
.	.	O
Primary	JJ	O
antibody	NN	O
is	VBZ	O
added	VBN	O
at	IN	O
1:500	CD	O
dilution	NN	O
(	(	O
Goat	NNP	O
anti-RSV	JJ	O
polyclonal	JJ	O
antibody	NN	O
(	(	O
Chemicon	NNP	O
Cat	NNP	O
#	#	O
AB1128	NNP	O
)	)	O
)	)	O
in	IN	O
PBS+5	NNP	O
%	NN	O
Milk	NNP	O
Protein	NNP	O
for	IN	O
1	CD	O
hr	NN	O
.	.	O
Plates	NNS	O
are	VBP	O
washed	VBN	O
again	RB	O
3×	CD	O
with	IN	O
5	CD	O
%	NN	O
milk	NN	O
in	IN	O
PBS	NNP	O
.	.	O
Secondary	JJ	O
antibody	NN	O
is	VBZ	O
added	VBN	O
at	IN	O
1:500	CD	O
dilution	NN	O
in	IN	O
5	CD	O
%	NN	O
milk	NN	O
protein	NN	O
in	IN	O
PBS	NNP	O
(	(	O
ImmunoPure	NNP	O
Rabbit	NNP	O
anti-goat	JJ	O
antibody	NN	O
IgG	NNP	O
(	(	O
H+L	NNP	O
)	)	O
Peroxidase	NNP	O
conjugated	VBN	O
)	)	O
(	(	O
Thermo	NNP	O
Scientific	NNP	O
,	,	O
Cat	NNP	O
#	#	O
31402	CD	O
)	)	O
)	)	O
for	IN	O
1	CD	O
hr	NN	O
.	.	O
Plates	NNS	O
are	VBP	O
washed	VBN	O
3×	CD	O
with	IN	O
1×PBS	CD	O
.	.	O
Plaques	NNS	O
are	VBP	O
visualized	VBN	O
by	IN	O
adding	VBG	O
1-Step	JJ	O
Chloronaphthol	NNP	O
substrate	NN	O
Pierce	NNP	O
,	,	O
Cat	NNP	O
#	#	O
34012	CD	O
)	)	O
,	,	O
200	CD	O
μL	NN	O
per	FW	O
well	NN	O
for	IN	O
10	CD	O
min	NN	O
.	.	O
Plates	NNS	O
are	VBP	O
rinsed	VBN	O
with	IN	O
water	NN	O
and	CC	O
allowed	VBN	O
to	TO	O
air	NN	O
dry	NNS	O
.	.	O
Plaques	NNS	O
are	VBP	O
counted	VBN	O
in	IN	O
each	DT	O
well	NN	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
absolute	JJ	O
numbers	NNS	O
of	IN	O
plaques	NNS	O
per	IN	O
μg	NN	O
of	IN	O
human	JJ	O
antibody	NN	O
and	CC	O
Synagis®	NNP	O
antibody	NN	O
is	VBZ	O
included	VBN	O
in	IN	O
the	DT	O
results	NNS	O
.	.	O
These	DT	O
data	NNS	O
show	VBP	O
that	IN	O
of	IN	O
the	DT	O
antibodies	NNS	O
tested	VBD	O
,	,	O
3D3	CD	O
is	VBZ	O
most	RBS	O
potent	JJ	O
.	.	O
3G12	CD	O
has	VBZ	O
an	DT	O
IC50	NNP	O
of	IN	O
15	CD	O
ng/ml	NN	O
or	CC	O
an	DT	O
affinity	NN	O
of	IN	O
100	CD	O
pM	NNS	O
according	VBG	O
to	TO	O
this	DT	O
assay	NN	O
,	,	O
whereas	WP	O
Synagis®	NNP	O
commercial	JJ	O
antibody	NN	O
has	VBZ	O
an	DT	O
IC50	NNP	O
of	IN	O
300	CD	O
ng/ml	NNS	O
corresponding	VBG	O
to	TO	O
an	DT	O
affinity	NN	O
of	IN	O
2	CD	O
nM	NNS	O
.	.	O
It	PRP	O
was	VBD	O
further	RBR	O
found	VBD	O
that	IN	O
Synagis®	NNP	O
and	CC	O
the	DT	O
anti-G	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
were	VBD	O
not	RB	O
synergistic	JJ	O
under	IN	O
these	DT	O
conditions	NNS	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
shows	NNS	O
neutralization	NN	O
of	IN	O
3G12	CD	O
antibody	NN	O
with	IN	O
respect	NN	O
to	TO	O
strain	VB	O
B	NNP	O
,	,	O
in	IN	O
comparison	NN	O
with	IN	O
Synagis®	NNP	O
.	.	O
The	DT	O
normalized	VBN	O
data	NNS	O
(	(	O
%	NN	O
of	IN	O
control	NN	O
)	)	O
are	VBP	O
based	VBN	O
on	IN	O
an	DT	O
absolute	NN	O
plaque	NN	O
number	NN	O
of	IN	O
160-180	JJ	O
per	IN	O
experiment	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
with	IN	O
in	IN	O
vitro	JJ	O
affinities	NNS	O
from	IN	O
1	CD	O
pM	NN	O
up	RB	O
to	TO	O
5	CD	O
nM	NNS	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
,	,	O
have	VBP	O
EC50	NNP	O
values	NNS	O
between	IN	O
10-100	JJ	O
ng/ml	NN	O
.	.	O
Example	JJ	O
7	CD	O
Anti-G	JJ	O
Prophylaxis	NNP	O
in	IN	O
Mice	NNP	O
The	DT	O
invention	NN	O
antibodies	NNS	O
,	,	O
Synagis®	NNP	O
,	,	O
and	CC	O
human	JJ	O
IgG1	NNP	O
were	VBD	O
tested	VBN	O
for	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
prevent	VB	O
RSV	NNP	O
infection	NN	O
in	IN	O
mice	NN	O
.	.	O
On	IN	O
day	NN	O
−1	NNP	O
,	,	O
prior	RB	O
to	TO	O
infection	NN	O
,	,	O
mice	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
injected	VBN	O
i.p	NN	O
.	.	O
with	IN	O
medium	NN	O
and	CC	O
PBS	NNP	O
.	.	O
In	IN	O
test	NN	O
groups	NNS	O
,	,	O
injection	NN	O
was	VBD	O
of	IN	O
0.15	CD	O
,	,	O
1.5	CD	O
and	CC	O
15	CD	O
mg/kg	NN	O
of	IN	O
antibodies	NNS	O
hIgG1	VBP	O
(	(	O
non-immune	JJ	O
,	,	O
isotype	JJ	O
control	NN	O
)	)	O
,	,	O
or	CC	O
3G12	CD	O
or	CC	O
3D3	CD	O
or	CC	O
Synagis®	NNP	O
.	.	O
This	DT	O
amounts	VBZ	O
to	TO	O
approximately	RB	O
3	CD	O
μg	NNS	O
,	,	O
30	CD	O
μg	NN	O
and	CC	O
300	CD	O
μg	NNS	O
per	IN	O
mouse	NN	O
.	.	O
On	IN	O
day	NN	O
0	CD	O
,	,	O
the	DT	O
mice	NN	O
were	VBD	O
inoculated	VBN	O
with	IN	O
1×106	CD	O
pfu	NNS	O
RSV	NNP	O
long-strain	NN	O
by	IN	O
intranasal	JJ	O
administration	NN	O
.	.	O
On	IN	O
days	NNS	O
0	CD	O
and	CC	O
5	CD	O
,	,	O
the	DT	O
lungs	NNS	O
,	,	O
bronchial	JJ	O
alveolar	JJ	O
lavage	NN	O
(	(	O
BAL	NNP	O
)	)	O
and	CC	O
serum	NN	O
were	VBD	O
collected	VBN	O
and	CC	O
body	NN	O
weight	NN	O
,	,	O
lung	NN	O
weight	NN	O
,	,	O
pfu	NN	O
in	IN	O
the	DT	O
lung	NN	O
lobe	NN	O
section	NN	O
,	,	O
viral	JJ	O
load	NN	O
(	(	O
by	IN	O
qPCR	NN	O
)	)	O
,	,	O
lung	JJ	O
histology	NN	O
,	,	O
total	JJ	O
leukocytes	NNS	O
,	,	O
FACS	NNP	O
,	,	O
and	CC	O
IFNγ	NNP	O
in	IN	O
BAL	NNP	O
were	VBD	O
all	DT	O
measured	VBN	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
based	VBN	O
on	IN	O
viral	JJ	O
lung	NN	O
load	NN	O
using	VBG	O
the	DT	O
plaque	NN	O
assay	VBP	O
from	IN	O
the	DT	O
foregoing	JJ	O
list	NN	O
.	.	O
The	DT	O
data	NN	O
in	IN	O
FIG	NNP	O
.	.	O
12	CD	O
show	NN	O
that	IN	O
3G12	CD	O
and	CC	O
3D3	CD	O
are	VBP	O
equally	RB	O
effective	JJ	O
as	IN	O
Synagis®	NNP	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
(	(	O
A	DT	O
typical	JJ	O
human	NN	O
dose	NN	O
for	IN	O
Synagis®	NNP	O
is	VBZ	O
15	CD	O
mg/kg	NN	O
in	IN	O
humans	NNS	O
.	.	O
)	)	O
Example	RB	O
8	CD	O
Therapeutic	JJ	O
Efficacy	NNP	O
of	IN	O
Antibodies	NNPS	O
to	TO	O
RSV-Ga/Gb	NNP	O
Antibodies	NNPS	O
to	TO	O
the	DT	O
conserved	VBN	O
motif	NN	O
on	IN	O
RSV-G	NNP	O
are	VBP	O
shown	VBN	O
to	TO	O
have	VB	O
therapeutic	JJ	O
efficacy	NN	O
.	.	O
Mice	NNP	O
were	VBD	O
infected	VBN	O
intra-nasally	RB	O
at	IN	O
day	NN	O
0	CD	O
with	IN	O
106	CD	O
pfu	NN	O
of	IN	O
RSV	NNP	O
,	,	O
then	RB	O
treated	VBD	O
at	IN	O
day	NN	O
3	CD	O
with	IN	O
3	CD	O
mg/kg	NNS	O
of	IN	O
antibody	NN	O
injected	JJ	O
i.p	NN	O
.	.	O
and	CC	O
assayed	VBN	O
at	IN	O
days	NNS	O
5	CD	O
and	CC	O
7	CD	O
for	IN	O
viral	JJ	O
load	NN	O
in	IN	O
bronchial	JJ	O
alveolar	JJ	O
lavage	NN	O
.	.	O
In	IN	O
this	DT	O
model	NN	O
,	,	O
the	DT	O
infection	NN	O
is	VBZ	O
more	RBR	O
readily	RB	O
cleared	VBN	O
naturally	RB	O
than	IN	O
in	IN	O
humans	NNS	O
.	.	O
Nonetheless	RB	O
,	,	O
the	DT	O
antibody	NN	O
treatment	NN	O
causes	VBZ	O
acceleration	NN	O
in	IN	O
viral	JJ	O
clearance	NN	O
in	IN	O
a	DT	O
dose	JJ	O
dependent	JJ	O
fashion	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
control	NN	O
antibody	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
bind	VB	O
RSV	NNP	O
(	(	O
FIG	NNP	O
.	.	O
13A	CD	O
)	)	O
.	.	O
Each	DT	O
treatment	NN	O
group	NN	O
had	VBD	O
5	CD	O
animals	NNS	O
,	,	O
and	CC	O
the	DT	O
results	NNS	O
are	VBP	O
statistically	RB	O
significant	JJ	O
.	.	O
As	IN	O
described	VBN	O
in	IN	O
WO	NNP	O
00/43040	CD	O
,	,	O
antibodies	NNS	O
to	TO	O
Substance	NNP	O
P	NNP	O
are	VBP	O
beneficial	JJ	O
in	IN	O
alleviating	VBG	O
the	DT	O
lung	NN	O
inflammation	NN	O
caused	VBN	O
by	IN	O
RSV	NNP	O
,	,	O
an	DT	O
animal	JJ	O
model	NN	O
for	IN	O
the	DT	O
prolonged	JJ	O
morbidity	NN	O
that	WDT	O
is	VBZ	O
the	DT	O
clinically	RB	O
important	JJ	O
feature	NN	O
of	IN	O
RSV	NNP	O
infection	NN	O
.	.	O
Up	IN	O
regulation	NN	O
of	IN	O
Substance	NNP	O
P	NNP	O
is	VBZ	O
dependent	JJ	O
on	IN	O
active	JJ	O
G	NNP	O
protein	NN	O
(	(	O
Haynes	NNP	B
,	,	I
L.	NNP	I
M.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
2003	CD	I
)	)	I
77:9831-9844	CD	I
)	)	O
.	.	O
Reduction	NN	O
in	IN	O
measures	NNS	O
of	IN	O
lung	NN	O
inflammation	NN	O
following	VBG	O
treatment	NN	O
with	IN	O
an	DT	O
antibody	NN	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
also	RB	O
been	VBN	O
observed	VBN	O
,	,	O
including	VBG	O
reduction	NN	O
in	IN	O
inflammatory	JJ	O
NK	NNP	O
and	CC	O
total	JJ	O
PMN	NNP	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
13B	CD	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
reduction	NN	O
in	IN	O
cytokines	NNS	O
,	,	O
e.g.	NN	O
,	,	O
IFNγ	NNP	O
(	(	O
FIG	NNP	O
.	.	O
13C	CD	O
)	)	O
.	.	O
In	IN	O
an	DT	O
additional	JJ	O
test	NN	O
,	,	O
on	IN	O
day	NN	O
0	CD	O
,	,	O
mice	NNS	O
were	VBD	O
inoculated	VBN	O
with	IN	O
106	CD	O
pfu	NN	O
of	IN	O
RSV	NNP	O
A-type	NNP	O
long	RB	O
strain	NN	O
by	IN	O
intranasal	JJ	O
administration	NN	O
.	.	O
On	IN	O
day	NN	O
3	CD	O
,	,	O
various	JJ	O
groups	NNS	O
of	IN	O
4-5	JJ	O
mice	NNS	O
were	VBD	O
treated	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
Group	NNP	O
1	CD	O
:	:	O
control	NN	O
group	NN	O
which	WDT	O
did	VBD	O
not	RB	O
receive	JJ	O
infection	NN	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
was	VBD	O
treated	VBN	O
with	IN	O
PBS	NNP	O
.	.	O
Group	NNP	O
2	CD	O
:	:	O
negative	JJ	O
control	NN	O
which	WDT	O
received	VBD	O
RSV	NNP	O
inoculation	NN	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
PBS	NNP	O
treatment	NN	O
on	IN	O
day	NN	O
3	CD	O
.	.	O
Group	NNP	O
3	CD	O
:	:	O
RSV	NNP	O
inoculation	NN	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
Synagis®	NNP	O
antibody	NN	O
i.p	NN	O
.	.	O
in	IN	O
saline	NN	O
at	IN	O
1	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
100	CD	O
μg	JJ	O
per	IN	O
mouse	NN	O
or	CC	O
0.05	CD	O
,	,	O
0.5	CD	O
or	CC	O
5	CD	O
mg/kg	NN	O
.	.	O
Group	NNP	O
4	CD	O
:	:	O
RSV	NNP	O
inoculated	VBD	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
administered	VBD	O
mAb	NNS	O
3D3	CD	O
in	IN	O
the	DT	O
same	JJ	O
protocol	NN	O
as	IN	O
Group	NNP	O
3	CD	O
.	.	O
Group	NNP	O
5	CD	O
:	:	O
received	VBN	O
RSV	NNP	O
inoculation	NN	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
administered	VBD	O
3G12	CD	O
in	IN	O
the	DT	O
same	JJ	O
amounts	NNS	O
as	IN	O
Groups	NNP	O
3	CD	O
and	CC	O
4	CD	O
.	.	O
Lungs	NNS	O
and	CC	O
BAL	NNP	O
fluid	NN	O
were	VBD	O
collected	VBN	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
3	CD	O
,	,	O
5	CD	O
,	,	O
7	CD	O
and	CC	O
10	CD	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
lung	NN	O
weight	NN	O
,	,	O
pfu	NN	O
in	IN	O
lung	NN	O
lobes	NNS	O
,	,	O
viral	JJ	O
load	NN	O
by	IN	O
qPCR	NN	O
,	,	O
lung	NN	O
histology	NN	O
,	,	O
total	JJ	O
leukocytes	NNS	O
,	,	O
FACS	NNP	O
were	VBD	O
measured	VBN	O
as	RB	O
well	RB	O
as	IN	O
IFNγ	NNP	O
in	IN	O
BAL	NNP	O
.	.	O
The	DT	O
results	NNS	O
for	IN	O
qPCR	NN	O
in	IN	O
the	DT	O
groups	NNS	O
administered	VBD	O
10	CD	O
μg	NN	O
of	IN	O
mAb	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
14	CD	O
.	.	O
As	IN	O
shown	VBN	O
,	,	O
the	DT	O
viral	JJ	O
titer	NN	O
in	IN	O
Synagis®-treated	NNP	O
and	CC	O
untreated	JJ	O
mice	NN	O
behaves	NNS	O
similarly	RB	O
at	IN	O
this	DT	O
relatively	RB	O
low	JJ	O
dose	NN	O
of	IN	O
antibody	NN	O
,	,	O
whereas	IN	O
both	DT	O
3D3	CD	O
treated	VBD	O
and	CC	O
3G12	CD	O
treated	JJ	O
mice	NN	O
had	VBD	O
greatly	RB	O
lower	JJR	O
titers	NNS	O
at	IN	O
the	DT	O
peak	NN	O
of	IN	O
infection	NN	O
on	IN	O
day	NN	O
5	CD	O
.	.	O
This	DT	O
experiment	NN	O
verifies	VBZ	O
that	IN	O
higher	JJR	O
affinity	NN	O
in	IN	O
vitro	NN	O
correlates	NNS	O
with	IN	O
higher	JJR	O
potency	NN	O
in	IN	O
vivo	NN	O
.	.	O
FIG	NNP	O
.	.	O
15	CD	O
shows	VBZ	O
the	DT	O
dose	JJ	O
response	NN	O
curve	NN	O
demonstrating	VBG	O
that	IN	O
3G12	CD	O
and	CC	O
3D3	CD	O
were	VBD	O
able	JJ	O
to	TO	O
lower	VB	O
the	DT	O
RSV	NNP	O
copy	NN	O
number	NN	O
as	IN	O
measured	VBN	O
by	IN	O
qPCR	NNS	O
on	IN	O
day	NN	O
7	CD	O
at	IN	O
lower	JJR	O
concentrations	NNS	O
than	IN	O
Synagis®	NNP	O
.	.	O
3D3	CD	O
was	VBD	O
particularly	RB	O
potent	JJ	O
,	,	O
again	RB	O
consistent	JJ	O
with	IN	O
having	VBG	O
higher	JJR	O
affinity	NN	O
in	IN	O
vitro	NN	O
.	.	O
Similarly	RB	O
,	,	O
when	WRB	O
qPCR	JJ	O
viral	JJ	O
counts	NNS	O
are	VBP	O
measured	VBN	O
on	IN	O
day	NN	O
10	CD	O
,	,	O
although	IN	O
viral	JJ	O
titers	NNS	O
are	VBP	O
naturally	RB	O
very	RB	O
low	JJ	O
at	IN	O
this	DT	O
point	NN	O
due	JJ	O
to	TO	O
natural	JJ	O
clearance	NN	O
by	IN	O
the	DT	O
mouse	NN	O
immune	NN	O
system	NN	O
,	,	O
3D3	CD	O
is	VBZ	O
approximately	RB	O
100	CD	O
times	NNS	O
more	RBR	O
potent	JJ	O
than	IN	O
Synagis®	NNP	O
at	IN	O
the	DT	O
various	JJ	O
dose	JJ	O
concentrations	NNS	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
16	CD	O
.	.	O
This	DT	O
experiment	JJ	O
highlights	VBZ	O
the	DT	O
utility	NN	O
of	IN	O
high	JJ	O
affinity	NN	O
antibodies	NNS	O
,	,	O
which	WDT	O
continue	VBP	O
to	TO	O
be	VB	O
effective	JJ	O
even	RB	O
when	WRB	O
the	DT	O
antigen	NN	O
concentration	NN	O
drops	NNS	O
.	.	O
The	DT	O
human	JJ	O
disease	NN	O
course	NN	O
is	VBZ	O
considerably	RB	O
more	RBR	O
prolonged	JJ	O
than	IN	O
in	IN	O
the	DT	O
mouse	NN	O
,	,	O
providing	VBG	O
a	DT	O
clear	JJ	O
motivation	NN	O
for	IN	O
use	NN	O
of	IN	O
an	DT	O
antibody	NN	O
that	WDT	O
continues	VBZ	O
to	TO	O
neutralize	VB	O
virus	NN	O
for	IN	O
an	DT	O
extended	JJ	O
time	NN	O
period	NN	O
.	.	O
In	IN	O
still	RB	O
further	JJ	O
experiments	NNS	O
,	,	O
mice	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
murine	JJ	O
anti-G	JJ	O
mAb	NN	O
or	CC	O
murine	VB	O
anti-F	JJ	O
mAb	NN	O
in	IN	O
groups	NNS	O
of	IN	O
four	CD	O
,	,	O
each	DT	O
experiment	NN	O
repeated	VBD	O
three	CD	O
times	NNS	O
.	.	O
The	DT	O
mice	NN	O
were	VBD	O
immunized	VBN	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
treated	VBN	O
with	IN	O
the	DT	O
antibodies	NNS	O
on	IN	O
day	NN	O
3	CD	O
,	,	O
and	CC	O
various	JJ	O
indications	NNS	O
of	IN	O
efficacy	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
days	NNS	O
3	CD	O
,	,	O
5	CD	O
and	CC	O
7	CD	O
.	.	O
As	IN	O
one	CD	O
index	NN	O
of	IN	O
effectiveness	NN	O
,	,	O
inflammatory	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
bronchial	JJ	O
alveolar	JJ	O
lavage	NN	O
(	(	O
BAL	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
with	IN	O
the	DT	O
results	NNS	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
17	CD	O
.	.	O
BAL	NNP	O
cells	NNS	O
per	IN	O
lung	NN	O
are	VBP	O
plotted	VBN	O
on	IN	O
the	DT	O
Y-axis	NN	O
from	IN	O
0	CD	O
to	TO	O
140×103	CD	O
.	.	O
The	DT	O
results	NNS	O
show	VBP	O
anti-F	JJ	O
mAb	NN	O
lowered	VBD	O
the	DT	O
BAL	NNP	O
cells	NNS	O
per	IN	O
lung	NN	O
at	IN	O
day	NN	O
5	CD	O
as	IN	O
compared	VBN	O
to	TO	O
isotype	VB	O
control	NN	O
non-immune	JJ	O
antibody	NN	O
,	,	O
whereas	IN	O
anti-sd-G	JJ	O
mAb	NN	O
lowered	VBD	O
the	DT	O
BAL	NNP	O
cell	NN	O
count	NN	O
substantially	RB	O
more	RBR	O
.	.	O
By	IN	O
day	NN	O
7	CD	O
,	,	O
the	DT	O
infection	NN	O
had	VBD	O
run	VBN	O
its	PRP$	O
course	NN	O
.	.	O
FIGS	NNP	O
.	.	O
18A	CD	O
and	CC	O
18B	CD	O
show	VBP	O
a	DT	O
comparison	NN	O
of	IN	O
effectiveness	NN	O
of	IN	O
anti-G	JJ	O
mAb	NN	O
(	(	O
murine	JJ	O
131-2G	CD	O
)	)	O
compared	VBN	O
with	IN	O
anti-G	JJ	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
obtained	VBN	O
from	IN	O
this	DT	O
antibody	NN	O
by	IN	O
cleavage	NN	O
with	IN	O
pepsin	NN	O
and	CC	O
removal	NN	O
of	IN	O
the	DT	O
Fc	NNP	O
fragments	NNS	O
using	VBG	O
immobilized	JJ	O
Protein	NNP	O
A	NNP	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
complement	NN	O
is	VBZ	O
important	JJ	O
for	IN	O
the	DT	O
anti-viral	JJ	O
effect	NN	O
of	IN	O
anti-G	JJ	O
antibodies	NNS	O
in	IN	O
vitro	NN	O
.	.	O
This	DT	O
is	VBZ	O
confirmed	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
18A	CD	O
where	WRB	O
the	DT	O
anti-viral	JJ	O
effect	NN	O
is	VBZ	O
measured	VBN	O
as	IN	O
pfu/g	NN	O
lung	NN	O
tissue	NN	O
.	.	O
Assays	NNS	O
were	VBD	O
conducted	VBN	O
as	IN	O
in	IN	O
Example	NNP	O
6	CD	O
.	.	O
The	DT	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragment	NN	O
of	IN	O
an	DT	O
anti-G	JJ	O
antibody	NN	O
,	,	O
which	WDT	O
lacks	VBZ	O
the	DT	O
Fc	NNP	O
portion	NN	O
of	IN	O
IgG	NNP	O
that	WDT	O
is	VBZ	O
needed	VBN	O
for	IN	O
complement	NN	O
mediated	VBN	O
activity	NN	O
,	,	O
is	VBZ	O
little	RB	O
better	JJR	O
than	IN	O
control	NN	O
in	IN	O
lowering	VBG	O
viral	JJ	O
load	NN	O
,	,	O
while	IN	O
anti-G	JJ	O
mAb	NN	O
is	VBZ	O
very	RB	O
effective	JJ	O
.	.	O
However	RB	O
,	,	O
when	WRB	O
inflammation	NN	O
is	VBZ	O
used	VBN	O
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
results	NNS	O
,	,	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
18B	CD	O
,	,	O
the	DT	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragment	NN	O
of	IN	O
anti-G	JJ	O
mAb	NN	O
is	VBZ	O
fully	RB	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
complete	JJ	O
antibody	NN	O
.	.	O
This	DT	O
experiment	NN	O
establishes	VBZ	O
that	IN	O
neutralization	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
is	VBZ	O
critical	JJ	O
to	TO	O
reducing	VBG	O
airway	RP	O
inflammation	NN	O
.	.	O
Since	IN	O
the	DT	O
virus	NN	O
actively	RB	O
secretes	VBZ	O
a	DT	O
soluble	JJ	O
form	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
,	,	O
and	CC	O
high	JJ	O
affinity	NN	O
binding	NN	O
is	VBZ	O
important	JJ	O
for	IN	O
neutralization	NN	O
of	IN	O
soluble	JJ	O
factors	NNS	O
,	,	O
the	DT	O
high	JJ	O
affinity	NN	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
expected	VBN	O
to	TO	O
have	VB	O
particular	JJ	O
utility	NN	O
for	IN	O
the	DT	O
anti-inflammatory	JJ	O
effect	NN	O
.	.	O
FIGS	NNP	O
.	.	O
19A	CD	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
show	VBP	O
the	DT	O
effect	NN	O
of	IN	O
anti-G	JJ	O
mAb	NN	O
on	IN	O
the	DT	O
production	NN	O
of	IN	O
IFNγ	NNP	O
in	IN	O
BAL	NNP	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
time	NN	O
of	IN	O
administration	NN	O
,	,	O
with	IN	O
the	DT	O
cytokine	NN	O
serving	NN	O
as	IN	O
a	DT	O
marker	NN	O
for	IN	O
airway	JJ	O
inflammation	NN	O
.	.	O
Control	NNP	O
non-immune	JJ	O
antibody	NN	O
in	IN	O
all	DT	O
cases	NNS	O
fails	VBP	O
to	TO	O
reduce	VB	O
the	DT	O
increase	NN	O
in	IN	O
IFNγ	NNP	O
production	NN	O
that	WDT	O
accompanies	VBZ	O
airway	RP	O
inflammation	NN	O
.	.	O
However	RB	O
,	,	O
whether	IN	O
anti-G	JJ	O
mAb	NN	O
is	VBZ	O
administered	VBN	O
at	IN	O
day	NN	O
−1	NNP	O
(	(	O
panel	NN	O
A	DT	O
)	)	O
,	,	O
at	IN	O
day	NN	O
+3	NNP	O
(	(	O
panel	NN	O
B	NNP	O
)	)	O
or	CC	O
even	RB	O
at	IN	O
day	NN	O
+5	NNP	O
(	(	O
panel	NN	O
C	NNP	O
)	)	O
,	,	O
a	DT	O
dramatic	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
IFNγ	NNP	O
at	IN	O
day	NN	O
7	CD	O
results	NNS	O
.	.	O
This	DT	O
experiment	NN	O
establishes	VBZ	O
utility	NN	O
of	IN	O
antibodies	NNS	O
to	TO	O
the	DT	O
central	JJ	O
conserved	VBD	O
motif	NN	O
of	IN	O
the	DT	O
RSV	NNP	O
G	NNP	O
protein	NN	O
for	IN	O
treating	VBG	O
inflammation	NN	O
well	RB	O
past	IN	O
the	DT	O
peak	NN	O
of	IN	O
viral	JJ	O
load	NN	O
.	.	O
Example	RB	O
9	CD	O
Specificity	NNP	O
of	IN	O
Endogenous	NNP	O
Antibodies	NNPS	O
in	IN	O
Infected	NNP	O
Subjects	NNP	O
Serum	NNP	O
samples	VBZ	O
from	IN	O
four	CD	O
elderly	JJ	O
adults	NNS	O
with	IN	O
severe	JJ	O
RSV	NNP	O
disease	NN	O
and	CC	O
with	IN	O
six	CD	O
elderly	JJ	O
adults	NNS	O
with	IN	O
mild	JJ	O
RSV	NNP	O
disease	NN	O
were	VBD	O
tested	VBN	O
for	IN	O
immunoreactivity	NN	O
with	IN	O
the	DT	O
synthetic	JJ	O
peptide	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
)	)	O
:	:	O
which	WDT	O
represents	VBZ	O
the	DT	O
conserved	JJ	O
region	NN	O
of	IN	O
RSV	NNP	O
G	NNP	O
protein	NN	O
from	IN	O
strain	NN	O
A2	NNP	O
.	.	O
The	DT	O
assay	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
ELISA	NNP	O
protocol	NN	O
described	VBD	O
in	IN	O
Example	NNP	O
5	CD	O
.	.	O
The	DT	O
levels	NNS	O
of	IN	O
antibodies	NNS	O
immunoreactive	VBP	O
with	IN	O
this	DT	O
peptide	JJ	O
correlate	NN	O
with	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
disease	NN	O
wherein	JJ	O
subjects	VBZ	O
with	IN	O
mild	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
disease	NN	O
exhibited	VBD	O
much	RB	O
higher	JJR	O
titers	NNS	O
than	IN	O
subjects	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
manifestations	NNS	O
of	IN	O
the	DT	O
infection	NN	O
(	(	O
see	VB	O
FIG	NNP	O
.	.	O
20	CD	O
)	)	O
.	.	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
antibodies	NNS	O
immunoreactive	VBP	O
with	IN	O
this	DT	O
portion	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	NN	O
are	VBP	O
effective	JJ	O
in	IN	O
ameliorating	VBG	O
infection	NN	O
.	.	O
Claims	NNS	O
(	(	O
22	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
2	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Child	NNP	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=40580419	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
3	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
1	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
After	IN	O
(	(	O
1	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
8	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
1	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
10	CD	O
)	)	O
Citations	NNPS	O
(	(	O
4	CD	O
)	)	O
Family	RB	O
Cites	VBZ	O
Families	NNS	O
(	(	O
10	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
4	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
35	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
2	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Owner	NNP	O
name	NN	O
:	:	O
TRELLIS	NNP	O
BIOSCIENCE	NNP	O
,	,	O
INC.	NNP	O
,	,	O
CALIFORNIA	NNP	O
Free	NNP	O
format	VBD	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNORS	NNP	O
:	:	O
KAUVAR	NNP	O
,	,	O
LAWRENCE	NNP	O
M.	NNP	O
;	:	O
COLLARINI	NNP	O
,	,	O
ELLEN	NNP	O
J.	NNP	O
;	:	O
KEYT	NNP	O
,	,	O
BRUCE	NNP	O
;	:	O
AND	CC	O
OTHERS	NNPS	O
;	:	O
SIGNING	NNP	O
DATES	NNP	O
FROM	NNP	O
20081222	CD	O
TO	NNP	O
20081226	CD	O
;	:	O
REEL/FRAME:024963/0327	NNP	O
Owner	NNP	O
name	NN	O
:	:	O
TRELLIS	NNP	O
RSV	NNP	O
HOLDINGS	NNP	O
,	,	O
INC.	NNP	O
,	,	O
CALIFORNIA	NNP	O
Free	NNP	O
format	VBD	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
TRELLIS	NNP	O
BIOSCIENCE	NNP	O
,	,	O
INC.	NNP	O
;	:	O
REEL/FRAME:028013/0399	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20120328	CD	O
Year	NN	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
